[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 107
6. Guimarães FS, Abud AP, Oliveira SM, Oliveira CC, César B, Andrade LF, Donatti L, Gabardo J, Trindade ES, Buchi DF: Stimulation of lymphocyte anti-melanoma activity by co-cultured macrophages activated by complex homeopathic medication. BMC Cancer; 2009;9:293
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stimulation of lymphocyte anti-melanoma activity by co-cultured macrophages activated by complex homeopathic medication.
  • A Brazilian complex homeopathic medication (CHM), used as an immune modulator, has been recommended for patients with depressed immune systems.
  • Previous studies in mice have demonstrated that the CHM activates macrophages, induces an increase in the number of leukocytes and improves the murine response against Sarcoma-180.
  • METHODS: Here we studied the interaction of mouse lymph node lymphocytes, co-cultured in vitro with macrophages in the presence or absence of the CHM, with B16F10 melanoma cells.
  • RESULTS: Lymphocytes co-cultured with macrophages in the presence of the CHM had greater anti-melanoma activity, reducing melanoma cell density and increasing the number of lysed tumor cells.
  • Overall, lymphocytes activated by treatment destroyed growing cancer cells more effectively than control lymphocytes.
  • CONCLUSION: Co-culture of macrophages with lymphocytes in the presence of the CHM enhanced the anti-cancer performance of lymphocytes against a very aggressive lineage of melanoma cells.
  • These results suggest that non-toxic therapies using CHMs are a promising alternative approach to the treatment of melanomas.
  • In addition, they are attractive combination-therapy candidates, which may enhance the efficacy of conventional medicines by improving the immune response against tumor cells.
  • [MeSH-major] Lymphocytes / drug effects. Macrophages / drug effects. Materia Medica / pharmacology. Melanoma / immunology
  • [MeSH-minor] Animals. Cell Line, Tumor. Cells, Cultured. Coculture Techniques. Cytotoxicity, Immunologic. Macrophage Activation / drug effects. Male. Mice

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2000 Jul-Aug;50(4):215-36; quiz 237-40 [10986965.001]
  • [Cites] Oncol Res. 2006;16(5):211-6 [17294801.001]
  • [Cites] Nat Immunol. 2001 Jul;2(7):585-9 [11429541.001]
  • [Cites] Eur J Cancer. 2001 Sep;37(13):1709-18 [11527700.001]
  • [Cites] Cytokine Growth Factor Rev. 2002 Apr;13(2):169-83 [11900992.001]
  • [Cites] Cell. 2002 Jun 14;109(6):707-18 [12086670.001]
  • [Cites] Cancer Cell. 2002 Sep;2(3):169-71 [12242147.001]
  • [Cites] Science. 2002 Oct 25;298(5594):850-4 [12242449.001]
  • [Cites] J Submicrosc Cytol Pathol. 2002 Jul;34(3):255-63 [12408358.001]
  • [Cites] Micron. 2008 Jun;39(4):461-70 [17379529.001]
  • [Cites] J Cell Biochem. 2008 Jul 1;104(4):1364-77 [18286468.001]
  • [Cites] Nat Rev Immunol. 2003 Jan;3(1):23-35 [12511873.001]
  • [Cites] Cytokine Growth Factor Rev. 2003 Oct;14(5):361-8 [12948519.001]
  • [Cites] Mol Cell Biochem. 2003 Nov;253(1-2):339-45 [14619985.001]
  • [Cites] Genet Mol Res. 2003;2(2):223-8 [14966688.001]
  • [Cites] Cell Struct Funct. 1993 Dec;18(6):399-407 [8033221.001]
  • [Cites] Lancet. 2005 Feb 19-25;365(9460):687-701 [15721476.001]
  • [Cites] Homeopathy. 2005 Jan;94(1):26-32 [15751331.001]
  • [Cites] J Infect. 2005 Aug;51(2):157-64 [16038768.001]
  • [Cites] J Am Coll Surg. 2005 Sep;201(3):418-25 [16125076.001]
  • [Cites] Micron. 2006;37(3):277-87 [16364649.001]
  • [Cites] Eur J Cancer. 2006 Feb;42(3):282-9 [16376071.001]
  • [Cites] Annu Rev Immunol. 2006;24:175-208 [16551247.001]
  • [Cites] Eur J Cancer. 2006 Apr;42(6):745-50 [16517151.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3130-6 [16707612.001]
  • [Cites] J Infect. 2006 Jun;52(6):420-32 [16386798.001]
  • [Cites] Immunol Lett. 2006 Aug 15;106(2):135-43 [16769127.001]
  • [Cites] Cell Biol Int. 2006 Oct;30(10):808-16 [16884931.001]
  • [Cites] Nat Immunol. 2001 Jun;2(6):487-92 [11376334.001]
  • (PMID = 19698142.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Materia Medica
  • [Other-IDs] NLM/ PMC2749867
  •  go-up   go-down


7. Shi J, Tong Y, Shen JG, Li HX: Effectiveness and safety of herbal medicines in the treatment of irritable bowel syndrome: a systematic review. World J Gastroenterol; 2008 Jan 21;14(3):454-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effectiveness and safety of herbal medicines in the treatment of irritable bowel syndrome: a systematic review.
  • AIM: To explore the efficacy and safety of herbal medicines (HM) in the treatment of irritable bowel syndrome (IBS).
  • We reviewed randomized controlled trials on the treatment of IBS with and without HM.
  • Four of these studies were of good quality, while the remaining 18 studies involving 17 Chinese herbal medicine (CHM) formulas were of poor quality.
  • CONCLUSION: Herbal medicines have therapeutic benefit in IBS, and adverse events are seldom reported in literature.
  • It is necessary to conduct rigorous, well-designed clinical trials to evaluate their effectiveness and safety in the treatment of IBS.
  • [MeSH-major] Drugs, Chinese Herbal / therapeutic use. Irritable Bowel Syndrome / drug therapy

  • Genetic Alliance. consumer health - Irritable Bowel Syndrome.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cochrane Database Syst Rev. 2001;(2):CD002231 [11406038.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Nov;4(11):1302-8 [17081807.001]
  • [Cites] Arch Intern Med. 2003 Feb 10;163(3):265-74 [12578506.001]
  • [Cites] Rev Gastroenterol Disord. 2003;3 Suppl 2:S18-24 [12775999.001]
  • [Cites] N Engl J Med. 2003 Oct 2;349(14):1360-8 [14523145.001]
  • [Cites] Zhongguo Zhong Xi Yi Jie He Za Zhi. 2003 Nov;23(11):823-5 [14666762.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Feb 1;19(3):271-9 [14984373.001]
  • [Cites] Control Clin Trials. 1996 Feb;17(1):1-12 [8721797.001]
  • [Cites] Control Clin Trials. 1998 Apr;19(2):159-66 [9551280.001]
  • [Cites] JAMA. 1998 Nov 11;280(18):1585-9 [9820260.001]
  • [Cites] Gut. 1999 Sep;45 Suppl 2:II43-7 [10457044.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Mar;3(3):237-47 [15765443.001]
  • [Cites] Br Med Bull. 2004;72:15-29 [15767561.001]
  • [Cites] Gastroenterol Clin North Am. 2005 Jun;34(2):189-204 [15862929.001]
  • [Cites] Neurogastroenterol Motil. 2005 Jun;17(3):317-24 [15916618.001]
  • [Cites] Neurogastroenterol Motil. 2005 Jun;17(3):332-40 [15916620.001]
  • [Cites] BMC Med Res Methodol. 2005;5:26 [16109176.001]
  • [Cites] Scand J Gastroenterol. 2005 Aug;40(8):936-43 [16173134.001]
  • [Cites] Digestion. 2002;65(3):161-71 [12138321.001]
  • (PMID = 18200670.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal
  • [Number-of-references] 39
  • [Other-IDs] NLM/ PMC2679136
  •  go-up   go-down


8. Wang SW, Pan SL, Huang YC, Guh JH, Chiang PC, Huang DY, Kuo SC, Lee KH, Teng CM: CHM-1, a novel synthetic quinolone with potent and selective antimitotic antitumor activity against human hepatocellular carcinoma in vitro and in vivo. Mol Cancer Ther; 2008 Feb;7(2):350-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CHM-1, a novel synthetic quinolone with potent and selective antimitotic antitumor activity against human hepatocellular carcinoma in vitro and in vivo.
  • In this study, 2'-fluoro-6,7-methylenedioxy-2-phenyl-4-quinolone (CHM-1), a synthetic 6,7-substituted 2-phenyl-4-quinolone, was identified as a potent and selective antitumor agent in human hepatocellular carcinoma.
  • CHM-1 induced growth inhibition of HA22T, Hep3B, and HepG2 cells in a concentration-dependent manner but did not obviously impair the viability of normal cells at the IC(50) for liver cancer cells.
  • CHM-1-induced apoptosis was also characterized by immunofluorescence microscopy.
  • CHM-1 interacted with tubulin at the colchicine-binding site, markedly inhibited tubulin polymerization both in vitro and in vivo, and disrupted microtubule organization.
  • CHM-1 caused cell cycle arrest at G(2)-M phase by activating Cdc2/cyclin B1 complex activity.
  • CHM-1-induced cell death, activation of Cdc2 kinase activity, and elevation of MPM2 phosphoepitopes were profoundly attenuated by roscovitine, a specific cyclin-dependent kinase inhibitor.
  • CHM-1 did not modulate the caspase cascade, and the pan-caspase-inhibitor z-VAD-fmk did not abolish CHM-1-induced cell death.
  • However, CHM-1 induced the translocation of apoptosis-inducing factor (AIF) from mitochondria to the nucleus.
  • Small interfering RNA targeting of AIF substantially attenuated CHM-1-induced AIF translocation.
  • Importantly, CHM-1 inhibited tumor growth and prolonged the lifespan in mice inoculated with HA22T cells.
  • In conclusion, we show that CHM-1 exhibits a novel antimitotic antitumor activity against human hepatocellular carcinoma both in vitro and in vivo via a caspase-independent pathway.
  • CHM-1 is a promising chemotherapeutic agent worthy of further development into a clinical trial candidate for treating cancer, especially hepatocellular carcinoma.
  • [MeSH-major] Carcinoma, Hepatocellular / drug therapy. Dioxoles / pharmacology. Dioxoles / therapeutic use. Liver Neoplasms / drug therapy. Quinolones / pharmacology. Quinolones / therapeutic use
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Apoptosis / drug effects. Apoptosis Inducing Factor / metabolism. Caspases / metabolism. Cell Division / drug effects. Cell Proliferation / drug effects. G2 Phase / drug effects. Humans. Male. Mice. Mice, SCID. Microtubules / drug effects. Microtubules / metabolism. Models, Biological. Substrate Specificity. Tumor Cells, Cultured. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18281518.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA17625
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2'-fluoro-6,7-methylenedioxy-2-phenyl-4-quinolone; 0 / Antineoplastic Agents; 0 / Apoptosis Inducing Factor; 0 / Dioxoles; 0 / Quinolones; EC 3.4.22.- / Caspases
  •  go-up   go-down


9. Bruchim I, Kidron D, Amiel A, Altaras M, Fejgin MD: Complete hydatidiform mole and a coexistent viable fetus: report of two cases and review of the literature. Gynecol Oncol; 2000 Apr;77(1):197-202
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete hydatidiform mole and a coexistent viable fetus: report of two cases and review of the literature.
  • OBJECTIVE: The aim of this study was to report the clinical features, management, and outcome of two cases of complete hydatidiform mole with a coexisting viable fetus and to review the literature.
  • PATIENTS: In this article, we report on the well-documented follow-up of 2 cases of twin pregnancies with complete hydatidiform mole and a viable fetus, both of which ended with the delivery of a normal infant at 41 and 26 weeks of gestation.
  • Since 1977, the year in which complete and partial moles were characterized as distinct pathologic entities, 15 cases (including our 2) have been reported.
  • RESULTS: Persistent GTT developed in eight patients (53.3%) and four patients (27.7%) developed metastatic disease.
  • Seventy-five percent patients with persistent GTT were treated with single-agent chemotherapy.
  • CONCLUSION: Complete hydatidiform mole and coexistent fetus is a rare occurrence and is associated with an increased risk of persistent gestational trophoblastic tumor.
  • Based on currently available information, it seems that in the presence of a stable pregnancy, normal karyotype, and a normal sonogram it is reasonable to allow the pregnancy to continue.
  • [MeSH-major] Fetal Viability. Hydatidiform Mole / pathology. Pregnancy Complications, Neoplastic / pathology. Trophoblastic Neoplasms / etiology. Uterine Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Ovulation Induction. Pregnancy. Pregnancy Outcome. Risk Factors. Twins

  • Genetic Alliance. consumer health - Hydatidiform mole.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Academic Press.
  • [CommentIn] Gynecol Oncol. 2000 Dec;79(3):524-5 [11104636.001]
  • (PMID = 10739712.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 19
  •  go-up   go-down


10. Limpongsanurak S: Prophylactic actinomycin D for high-risk complete hydatidiform mole. J Reprod Med; 2001 Feb;46(2):110-6
Hazardous Substances Data Bank. DACTINOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prophylactic actinomycin D for high-risk complete hydatidiform mole.
  • OBJECTIVE: To evaluate the effectiveness of one course of prophylactic actinomycin D in reducing the malignant sequelae requiring chemotherapy in high-risk complete hydatidiform mole (CHM).
  • Sixty cases of CHM classified as high risk were recruited and randomly allocated to a chemoprophylactic or control group.
  • Within one week after evacuation of molar tissues, actinomycin D was administered in the chemoprophylactic group.
  • Patients in the control group were given only intravenous fluid and analgesic drugs.
  • The number of patients with malignant sequelae who required therapeutic chemotherapy after evacuation of hydatidiform mole in each group was recorded.
  • The risk reduction of malignant sequelae with one course of actinomycin D chemoprophylaxis in high-risk CHM was 72.4% (95% CI = 26.7-89.6%) (P = .005).
  • The side effects of prophylactic chemotherapy were stomatitis, nausea/vomiting, sore throat with oral ulcer and hair loss.
  • CONCLUSION: One course of actinomycin D given as chemoprophylaxis decreased by 72.4% malignant sequelae after evacuation of molar tissue in patients with high-risk CHM.
  • This may be particularly beneficial in patients with high-risk CHM who cannot be followed closely, whose compliance is in question and for whom hormonal follow-up is not available or unreliable.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Dactinomycin / therapeutic use. Hydatidiform Mole / prevention & control. Uterine Neoplasms / prevention & control
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Double-Blind Method. Female. Humans. Incidence. Pregnancy. Risk Factors

  • Genetic Alliance. consumer health - Hydatidiform mole.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11255809.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 1CC1JFE158 / Dactinomycin
  •  go-up   go-down


11. Steigrad SJ, Robertson G, Kaye AL: Serial hCG and ultrasound measurements for predicting malignant potential in multiple pregnancies associated with complete hydatidiform mole: a report of 2 cases. J Reprod Med; 2004 Jul;49(7):554-8
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serial hCG and ultrasound measurements for predicting malignant potential in multiple pregnancies associated with complete hydatidiform mole: a report of 2 cases.
  • BACKGROUND: Multiple pregnancy complicated by the presence of a complete hydatidiform mole (CHM) is a rare clinical entity.
  • CASES: Case 1 presented in the first trimester with a twin pregnancy associated with a CHM.
  • In the absence of other complications, the pregnancy was monitored with serial beta-human chorionic gonadotropin (beta-hCG) and ultrasound measurements.
  • A reduction in molar volume suggested regression of the CHM.
  • The pregnancy was successfully carried to term with no progress of the CHM.
  • Case 2 had a triplet pregnancy resulting from in vitro fertilization with a CHM detected in the first trimester.
  • The pregnancy was complicated by episodes of antepartum hemorrhage (APH).
  • Further, the molar volume continued to increase.
  • The patient was treated with single-agent chemotherapy, with complete resolution.
  • CONCLUSION: The combination of serial ultrasound molar volume measurements with serial beta-hCG estimation may assist the clinician in predicting which of these rare complicated pregnancies will result in the development of trophoblastic neoplasia.
  • [MeSH-major] Chorionic Gonadotropin, beta Subunit, Human / blood. Hydatidiform Mole / ultrasonography. Pregnancy Complications, Neoplastic / ultrasonography. Pregnancy, Multiple. Uterine Neoplasms / ultrasonography
  • [MeSH-minor] Adult. Cell Transformation, Neoplastic. Female. Humans. Predictive Value of Tests. Pregnancy

  • Genetic Alliance. consumer health - Hydatidiform mole.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15305827.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human
  •  go-up   go-down


12. Seckl MJ, Dhillon T, Dancey G, Foskett M, Paradinas FJ, Rees HC, Sebire N, Vigushin DM, Newlands ES: Increased gestational age at evacuation of a complete hydatidiform mole: does it correlate with increased risk of requiring chemotherapy? J Reprod Med; 2004 Jul;49(7):527-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased gestational age at evacuation of a complete hydatidiform mole: does it correlate with increased risk of requiring chemotherapy?
  • OBJECTIVE: To assess whether a complete hydatidiform mole (CHM) carries an increased risk of later requiring chemotherapy in pregnancies continued to term.
  • STUDY DESIGN: The Charing Cross gestational trophoblastic neoplasia (GTN) database was screened between 1973 and 2002 to identify registered singleton CHMs with a known gestational age at the time of evacuation.
  • Of the 8,313 cases 2,800 were centrally histopathologically reviewed by us and confirmed as CHM.
  • RESULTS: For the total population, including non-centrally reviewed patients, evacuation occurring in the first, second or third trimester was associated with a treatment rate of 13.9% (601 of 4,333), 10.8% (412 of 3,803) and 5.1% (9 of 177), respectively.
  • In patientsfor whom a central pathologic review had been performed to confirm the diagnosis, the treatment rates were 27.7% (525 of 1,897), 27% (241 of 893) and 20% (2 of 10).
  • The higher apparent treatment rates reflect an error in the denominator as we do not review all nontreated cases.
  • In the total population, evacuation in the third trimester correlated with a reduction in risk of subsequent treatment (P<.001).
  • CONCLUSION: There is no evidence that delayed evacuation/delivery of singleton CHM increases the risk of subsequently requiring chemotherapy.
  • [MeSH-major] Cell Transformation, Neoplastic. Hydatidiform Mole / surgery. Uterine Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Female. Gestational Age. Humans. Obstetric Surgical Procedures / methods. Pregnancy. Risk Factors. Time Factors

  • Genetic Alliance. consumer health - Hydatidiform mole.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15305823.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


13. Horn LC, Kowalzik J, Bilek K, Richter CE, Einenkel J: Clinicopathologic characteristics and subsequent pregnancy outcome in 139 complete hydatidiform moles. Eur J Obstet Gynecol Reprod Biol; 2006 Sep-Oct;128(1-2):10-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic characteristics and subsequent pregnancy outcome in 139 complete hydatidiform moles.
  • OBJECTIVE: The most common form of gestational trophoblastic disease is the complete hydatidiform mole (CHM).
  • The study reports our experience of clinicopathologic characteristics and subsequent pregnancy outcome of patients with CHM.
  • STUDY DESIGN: One hundred fifty-one subsequent cases with initial diagnosis of CHM were re-evaluated histopathologically.
  • Clinical characteristics, the need for chemotherapy and subsequent pregnancy outcome were evaluated.
  • RESULTS: Twelve out of 151 cases were re-evaluated as hydropic abortion, as partial hydatidiform moles or were insufficient for morphologic examination and therefore excluded from further analysis.
  • Twenty-six patients (19%) required chemotherapy because of gestational trophoblastic neoplasia (GTN; low-risk: 23 out of 26).
  • The subsequent pregnancy rate was 15% (21/139).
  • Four women presented with recurrent CHM with a spontaneous normalization of HCG levels after D&C.
  • CONCLUSIONS: The clinical and morphologic diagnosis of CHM is a challenge, and diagnosis as well as treatment should be multidisciplinary and centralised.
  • One fifth of CHM are at risk of a GTN, but the cure rate is 100% with adequate management.
  • Pregnancy outcome following CHM is complicated by an increased risk of abortion.
  • [MeSH-major] Hydatidiform Mole / complications. Pregnancy Outcome. Uterine Neoplasms / complications
  • [MeSH-minor] Abortion, Spontaneous / etiology. Adolescent. Adult. Female. Humans. Middle Aged. Pregnancy. Recurrence. Retrospective Studies

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16530318.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


1
Advertisement
4. Baasanjav B, Usui H, Kihara M, Kaku H, Nakada E, Tate S, Mitsuhashi A, Matsui H, Shozu M: The risk of post-molar gestational trophoblastic neoplasia is higher in heterozygous than in homozygous complete hydatidiform moles. Hum Reprod; 2010 May;25(5):1183-91
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The risk of post-molar gestational trophoblastic neoplasia is higher in heterozygous than in homozygous complete hydatidiform moles.
  • BACKGROUND: Complete hydatidiform mole (CHM) is a high-risk pregnancy for gestational trophoblastic neoplasia (GTN).
  • Patients with CHM have a 10-30% chance of trophoblastic sequelae.
  • CHM includes androgenic homozygous (monospermic) and androgenic heterozygous (dispermic) moles.
  • It is controversial whether the risk of GTN is higher with heterozygous than with homozygous CHM.
  • A prospective cohort study was conducted to assess risk of GTN in homozygous and heterozygous CHM using short tandem repeat (STR) polymorphisms, and a meta-analysis of previous reports.
  • METHODS: Twenty-eight consecutive molar pregnancies were evacuated and followed by regular hCG measurements to detect GTN.
  • Cytogenesis of the mole was determined by STR polymorphisms of molar tissue and parental blood.
  • RESULTS: Of 28 molar pregnancies, 24 were homozygous and three were heterozygous CHM.
  • The remaining mole was diandric triploidy (a partial hydatidiform mole).
  • Of the 24 homozygous CHMs, six (25%) cases developed GTN and received chemotherapy.
  • Meanwhile, all three cases (100%) of heterozygous mole developed GTN and needed chemotherapy.
  • The GTN risk was higher in heterozygous (P = 0.029, Fisher's exact test) than homozygous moles.
  • A systematic review revealed only five previous reports (with more than 15 cytogenetically diagnosed cases), and the pooled relative risk of persistent GTN for heterozygous mole was not significant (odds ratio, 2.0; 95% confidence interval, 0.98-4.07).
  • CONCLUSIONS: Heterozygous CHM had a higher risk for GTN than homozygous CHM.
  • [MeSH-major] Hydatidiform Mole / genetics. Uterine Neoplasms / genetics
  • [MeSH-minor] Adult. Chorionic Gonadotropin / blood. Cohort Studies. Female. Heterozygote. Homozygote. Humans. Male. Microsatellite Repeats. Middle Aged. Pregnancy. Prospective Studies. Risk Factors. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20208060.001).
  • [ISSN] 1460-2350
  • [Journal-full-title] Human reproduction (Oxford, England)
  • [ISO-abbreviation] Hum. Reprod.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin
  •  go-up   go-down


15. Yamada T, Matsuda T, Kudo M, Yamada T, Moriwaki M, Nishi S, Ebina Y, Yamada H, Kato H, Ito T, Wake N, Sakuragi N, Minakami H: Complete hydatidiform mole with coexisting dichorionic diamniotic twins following testicular sperm extraction and intracytoplasmic sperm injection. J Obstet Gynaecol Res; 2008 Feb;34(1):121-4
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete hydatidiform mole with coexisting dichorionic diamniotic twins following testicular sperm extraction and intracytoplasmic sperm injection.
  • We present the first report of complete hydatidiform mole (HM) with coexisting dichorionic diamniotic twins.
  • This pregnancy was achieved after testicular sperm extraction and intracytoplasmic sperm injection (ICSI) for azoospermia in the woman's husband.
  • Standard in vitro fertilization may cause multisperm fertilization and increase triploid partial HM and complete HM, which arise from dispermic fertilization.
  • In our case, paternal isodisomy in the molar tissue was confirmed by microsatellite analysis suggesting that it resulted from duplication of a haploid paternal genome following monospermic fertilization of an inactivated oocyte or from monospermic fertilization of an inactivated oocyte with a diploid sperm.
  • Although the patient was eager to continue the pregnancy, the size of the HM component increased rapidly and termination of the pregnancy was required for pre-eclampsia-like symptoms at 15 weeks of gestation.
  • After the operation, chemotherapy was initiated for persistent trophoblastic disease.
  • [MeSH-major] Hydatidiform Mole / diagnosis. Twins. Ultrasonography, Prenatal. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Abortion, Induced. Adult. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Pregnancy. Sperm Injections, Intracytoplasmic

  • Genetic Alliance. consumer health - Hydatidiform mole.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18226144.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


16. Lurain JR: Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. Am J Obstet Gynecol; 2010 Dec;203(6):531-9
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole.
  • Gestational trophoblastic disease includes hydatidiform mole (complete and partial) and gestational trophoblastic neoplasia (invasive mole, choriocarcinoma, placental site trophoblastic tumor, and epithelioid trophoblastic tumor).
  • Particular emphasis is given to management of hydatidiform mole, including evacuation, twin mole/normal fetus pregnancy, prophylactic chemotherapy, and follow-up.
  • [MeSH-major] Gestational Trophoblastic Disease / drug therapy. Gestational Trophoblastic Disease / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Abortion, Therapeutic / methods. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Choriocarcinoma / diagnosis. Choriocarcinoma / drug therapy. Choriocarcinoma / mortality. Choriocarcinoma / pathology. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Hydatidiform Mole / drug therapy. Hydatidiform Mole / pathology. Hysterectomy / methods. Pregnancy. Risk Assessment. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Gestational Trophoblastic Disease.
  • Genetic Alliance. consumer health - Hydatidiform mole.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20728069.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


17. Adewole IF, Oladokun A, Fawole AO, Olawuyi JF, Adeleye JA: Fertility regulatory methods and development of complications after evacuation of complete hydatidiform mole. J Obstet Gynaecol; 2000 Jan;20(1):68-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fertility regulatory methods and development of complications after evacuation of complete hydatidiform mole.
  • In a prospective, simple randomised study, we evaluated the relative efficacy of hormonal (oral contraceptive pill) and non-hormonal (intrauterine contraceptive device) methods of contraception as fertility regulatory agents in patients with complete hydatidiform moles and assessed the development of complications and sequelae if any, following their use.
  • Five patients (two on OCP, and three on IUCD) developed a gestational trophoblastic tumour and were admitted for chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15512472.001).
  • [ISSN] 0144-3615
  • [Journal-full-title] Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology
  • [ISO-abbreviation] J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  •  go-up   go-down


18. Kendall A, Gillmore R, Newlands E: Chemotherapy for trophoblastic disease: current standards. Curr Opin Obstet Gynecol; 2002 Feb;14(1):33-8
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy for trophoblastic disease: current standards.
  • Gestational trophoblastic diseases comprise a rare spectrum of disorders in which the normal regulatory mechanisms controlling the behaviour of trophoblastic tissue are lost.
  • They vary from the benign complete and partial hydatidiform moles to the frankly malignant choriocarcinoma and placental site trophoblastic tumours.
  • The majority will be cured by suction curettage, followed by human chorionic gonadotrophin screening, but some will go on to need chemotherapy.
  • Patients should have their treatment stratified according to various prognostic factors in order to ensure firstly their disease is eliminated and secondly to reduce the incidence of long-term treatment complications.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Trophoblastic Neoplasms / drug therapy. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Brain Neoplasms / radiotherapy. Brain Neoplasms / secondary. Cyclophosphamide / administration & dosage. Dactinomycin / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Female. Humans. Leucovorin / administration & dosage. Methotrexate / administration & dosage. Neoplasm Staging. Pregnancy. Prognosis. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11801874.001).
  • [ISSN] 1040-872X
  • [Journal-full-title] Current opinion in obstetrics & gynecology
  • [ISO-abbreviation] Curr. Opin. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 13
  •  go-up   go-down


19. Kendall A, Gillmore R, Newlands E: Chemotherapy for trophoblastic disease: current standards. Expert Rev Anticancer Ther; 2003 Feb;3(1):48-54
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy for trophoblastic disease: current standards.
  • Gestational trophoblastic diseases comprise a rare spectrum of disorders in which the normal regulatory mechanisms controlling the behavior of trophoblastic tissue are lost.
  • They vary from the benign complete and partial hydatidiform moles to the frankly malignant choriocarcinoma and placental site trophoblastic tumors.
  • The majority will be cured by suction curettage, followed by human chorionic gonadotrphin screening but some will go on to need chemotherapy.
  • Patients should have their treatment stratified according to various prognostic factors in order to ensure firstly their disease is eliminated and secondly to reduce the incidence of long-term treatment complications.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Trophoblastic Neoplasms / drug therapy. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Clinical Trials as Topic. Drug Resistance, Neoplasm. Female. Humans. Neoplasm Staging. Placenta / pathology. Pregnancy. Prognosis. Risk Assessment

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12597349.001).
  • [ISSN] 1473-7140
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 14
  •  go-up   go-down


20. Ino K, Mitsui T, Nomura S, Kikkawa F, Mizutani S: Complete remission of gestational choriocarcinoma with choroidal metastasis treated with systemic chemotherapy alone: case report and review of literature. Gynecol Oncol; 2001 Dec;83(3):601-4
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission of gestational choriocarcinoma with choroidal metastasis treated with systemic chemotherapy alone: case report and review of literature.
  • She had undergone evacuation of a complete hydatidiform mole 32 months prior to the presentation.
  • The patient received 13 courses of combination chemotherapy, resulting in complete remission.
  • Radiotherapy and surgical treatment were unnecessary.
  • CONCLUSION: This is a very rare case of the successful treatment of gestational choriocarcinoma metastatic to the choroid using systemic chemotherapy alone.
  • [MeSH-major] Choriocarcinoma / drug therapy. Choriocarcinoma / secondary. Choroid Neoplasms / drug therapy. Choroid Neoplasms / secondary. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Female. Humans. Pregnancy. Remission Induction

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c)2001 Elsevier Science.
  • (PMID = 11733980.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 13
  •  go-up   go-down


21. Zhang M, Liu X, Li J, He L, Tripathy D: Chinese medicinal herbs to treat the side-effects of chemotherapy in breast cancer patients. Cochrane Database Syst Rev; 2007;(2):CD004921
MedlinePlus Health Information. consumer health - Herbal Medicine.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chinese medicinal herbs to treat the side-effects of chemotherapy in breast cancer patients.
  • BACKGROUND: Short term side-effects of chemotherapy include fatigue, nausea, vomiting, mucositis and myelosuppression or neutropenia.
  • These occur during the course of treatment and generally resolve within months of completion of chemotherapy.
  • OBJECTIVES: To assess the effectiveness and safety of Chinese medicinal herbs in alleviating chemotherapy-induced short term side effects in breast cancer patients.
  • SELECTION CRITERIA: Randomised controlled trials comparing chemotherapy with or without Chinese herbs in women with breast cancer.
  • MAIN RESULTS: We identified seven randomised controlled trials involving 542 breast cancer patients undergoing or having recently undergone chemotherapy.
  • All were of low quality and used CMH plus chemotherapy compared with chemotherapy alone.CMH combined with chemotherapy showed no statistically significant difference for the outcomes of phlebitis and alopecia.
  • AUTHORS' CONCLUSIONS: This review provides limited evidence about the effectiveness and safety of Chinese medicinal herbs in alleviating chemotherapy induced short term side effects.
  • Chinese medicinal herbs, when used together with chemotherapy, may offer some benefit to breast cancer patients in terms of bone marrow improvement and quality of life, but the evidence is too limited to make any confident conclusions.
  • Well designed clinical trials are required before any conclusions can be drawn about the effectiveness and safety of CHM in the management of breast cancer patients.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Breast Neoplasms / drug therapy. Drugs, Chinese Herbal / therapeutic use. Phytotherapy

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17443560.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drugs, Chinese Herbal
  • [Number-of-references] 45
  •  go-up   go-down


22. Chen S, Flower A, Ritchie A, Liu J, Molassiotis A, Yu H, Lewith G: Oral Chinese herbal medicine (CHM) as an adjuvant treatment during chemotherapy for non-small cell lung cancer: A systematic review. Lung Cancer; 2010 May;68(2):137-45
PubMed Health. DARE review .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral Chinese herbal medicine (CHM) as an adjuvant treatment during chemotherapy for non-small cell lung cancer: A systematic review.
  • Treatment options are limited and there is a need to explore alternatives.
  • This systematic review evaluates the role of Chinese herbal medicine (CHM) in association with chemotherapy for NSCLC.
  • METHODS: English and Chinese databases were searched for RCTs comparing CHM with conventional biomedical treatment or placebo.
  • There was a significant improvement in quality of life (QoL) (increased Karnofsky Performance Status) (RR 1.83, 95% CI 1.41-2.38, p<0.00001 for both stages III, IV only NSCLC and all stages NSCLC) and less anaemia (RR 0.37, 95% CI 0.15-0.91, p=0.03 for stages III, IV only NSCLC; p=0.005 for all stages NSCLC) and neutropenia (RR 0.42, 95% CI 0.22-0.82, p=0.01 for stages III, IV only NSCLC; p<0.00001 for all stages NSCLC) when CHM is combined with chemotherapy compared to chemotherapy alone.
  • CONCLUSION: It is possible that oral CHM used in conjunction with chemotherapy may improve QoL in NSCLC.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Chemotherapy, Adjuvant. Drugs, Chinese Herbal / administration & dosage. Lung Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Anemia / etiology. Anemia / prevention & control. Clinical Trials as Topic. Drug-Related Side Effects and Adverse Reactions. Humans. Neoplasm Staging. Neutropenia / etiology. Neutropenia / prevention & control. Quality of Life


23. Growdon WB, Wolfberg AJ, Goldstein DP, Feltmate CM, Chinchilla ME, Lieberman ES, Berkowitz RS: Low-risk gestational trophoblastic neoplasia and methotrexate resistance: predictors of response to treatment with actinomycin D and need for combination chemotherapy. J Reprod Med; 2010 Jul-Aug;55(7-8):279-84
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-risk gestational trophoblastic neoplasia and methotrexate resistance: predictors of response to treatment with actinomycin D and need for combination chemotherapy.
  • OBJECTIVE: To determine whether any clinical parameters predict the need for multiagent chemotherapy for treatment of low-risk gestational trophoblastic neoplasia (GTN) after the development of methotrexate (MTX) resistance.
  • STUDY DESIGN: We retrospectively analyzed clinical data from the New England Trophoblastic Disease Center from women with post-molar GTN between 1973 and 2003.
  • RESULTS: We analyzed data from 150 women (40 with partial mole, 110 with complete mole) who received single-agent MTX for low-risk GTN using FIGO and WHO scoring systems.
  • Of the 45 women who developed MTX resistance, the majority (37/45) of these patients received actinomycin D, with 10 patients ultimately requiring multiagent chemotherapy.
  • The requirement for multiagent chemotherapy following MTX resistance was associated with a beta-hCG > 600 mlU/mL 1 week following initial MTX therapy (p < 0.03).
  • Conversely, a beta-hCG < 600 mlU/mL 1 week following initial MTX therapy was as-sociated with a 93% probability of remission with actinomycin D alone.
  • CONCLUSION: The prognosis for patients with low-risk GTN following molar gestation is excellent, with 100% remission rate, though a small but significant proportion (7%) required multiagent chemotherapy.
  • The need for multiagent chemotherapy was associated with beta-hCG levels 1 week following initial MTX therapy.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Neoplasm. Gestational Trophoblastic Disease / drug therapy. Methotrexate / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Chorionic Gonadotropin, beta Subunit, Human / blood. Cyclophosphamide / therapeutic use. Dactinomycin / administration & dosage. Dactinomycin / therapeutic use. Etoposide / administration & dosage. Female. Humans. Middle Aged. Pregnancy. Registries. Remission Induction. Retrospective Studies. Uterine Neoplasms / drug therapy. Uterine Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20795339.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Chorionic Gonadotropin, beta Subunit, Human; 1CC1JFE158 / Dactinomycin; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate; MAC combination
  •  go-up   go-down


24. Mok TS, Yeo W, Johnson PJ, Hui P, Ho WM, Lam KC, Xu M, Chak K, Chan A, Wong H, Mo F, Zee B: A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity. Ann Oncol; 2007 Apr;18(4):768-74
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity.
  • BACKGROUND: Chinese herbal medicine (CHM) is a common complementary therapy used by patients with cancer for reduction of chemotherapy-induced toxic effects.
  • This study applied the highest standard of clinical trial methodology to examine the role of CHM in reducing chemotherapy-induced toxicity, while maintaining a tailored approach to therapy.
  • PATIENTS AND METHODS: Patients with early-stage breast or colon cancer who required postoperative adjuvant chemotherapy were eligible for the study.
  • Patients received either CHM or placebo packages with a corresponding serial number.
  • RESULTS: One hundred and twenty patients were accrued at the time of premature study termination.
  • The incidence of grade 3/4 anemia, leukopenia, neutropenia, and thrombocytopenia for the CHM and placebo groups were 5.4%, 47.3%, 52.7%, and 1.8% and 1.8%, 32.2%, 44.7%, and 3.6%, respectively (P = 0.27, 0.37, 0.63, and 0.13, respectively).
  • Incidence of grade 2 nausea was the only non-hematologic toxicity that was significantly reduced in the CHM group (14.6% versus 35.7%, P = 0.04).
  • CONCLUSIONS: Traditional CHM does not reduce the hematologic toxicity associated with chemotherapy.
  • CHM, however, does have a significant impact on control of nausea.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17229769.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drugs, Chinese Herbal
  •  go-up   go-down


25. Weaver DT, Fisher RA, Newlands ES, Paradinas FJ: Amniotic tissue in complete hydatidiform moles can be androgenetic. J Pathol; 2000 May;191(1):67-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amniotic tissue in complete hydatidiform moles can be androgenetic.
  • The purpose of this study was to determine whether amniotic tissue found associated with cases of complete hydatidiform mole (CM) was genetically identical to the CM, and therefore part of the molar pregnancy, or genetically dissimilar to the CM, suggesting derivation from a twin pregnancy.
  • DNA was prepared from formalin-fixed, paraffin-embedded blocks of tissue containing both CM and amnion.
  • Maternal DNA was prepared from decidual tissue in the same blocks, or from a maternal blood sample.
  • Fluorescent microsatellite genotyping was carried out to determine the origin of both the CM and the amniotic tissue.
  • In one of six cases examined, the amniotic tissue was genetically different from the CM and was therefore likely to be derived from a twin pregnancy.
  • In the five remaining cases, the amniotic tissue was genetically identical to the CM and was likely to be derived from the same conceptus.
  • It is concluded that androgenetic CM can support the development of amniotic tissue and that some early embryonic development may occur in CM.
  • The presence of amnion, or other fetal tissues, associated with molar tissue should not therefore always be considered indicative of a diagnosis of partial mole (PM).
  • [MeSH-major] Amnion / pathology. Hydatidiform Mole / genetics. Hydatidiform Mole / pathology. Pregnancy, Multiple
  • [MeSH-minor] Alleles. Female. Genotype. Humans. Microsatellite Repeats. Polymerase Chain Reaction. Polymorphism, Genetic. Pregnancy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 John Wiley & Sons, Ltd.
  • (PMID = 10767721.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  •  go-up   go-down


26. Amezcua CA, Bahador A, Naidu YM, Felix JC: Expression of human telomerase reverse transcriptase, the catalytic subunit of telomerase, is associated with the development of persistent disease in complete hydatidiform moles. Am J Obstet Gynecol; 2001 Jun;184(7):1441-6
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of human telomerase reverse transcriptase, the catalytic subunit of telomerase, is associated with the development of persistent disease in complete hydatidiform moles.
  • OBJECTIVE: This study was undertaken to determine the putative role of telomerase activity and human telomerase reverse transcriptase (hTERT) expression in the development of persistent disease in patients with a diagnosis of complete hydatidiform mole.
  • The role of telomerase in the pathogenesis of complete hydatidiform moles is not clearly understood.
  • STUDY DESIGN: Telomerase activity and hTERT expression were analyzed in the initial uterine evacuation specimen of 54 complete hydatidiform moles by use of the telomeric repeat amplification protocol assay and reverse transcription-polymerase chain reaction methods.
  • RESULTS: Among the 54 patients who were examined with a diagnosis of complete hydatidiform mole, persistent trophoblastic disease requiring postevacuation chemotherapy developed in 6.
  • Both telomerase activity and hTERT expression were detected in all 6 cases of persistent disease on the initial molar tissue sampled.
  • Among the 48 nonpersistent moles, telomerase activity was detected in 29 (60%) and hTERT expression was demonstrated in 26 (54%).
  • The detection of hTERT expression was significantly associated with the presence of persistent disease (P =.035).
  • Moreover, the absence of hTERT expression in molar tissue obtained from uterine evacuation demonstrated a 100% negative predictability in determining cases of complete mole that were nonpersistent.
  • CONCLUSIONS: Compared with telomerase activity, the expression of hTERT is significantly associated with the development of persistent disease in complete hydatidiform moles.
  • The absence of hTERT expression in the initial tissue sample from complete moles may have potential clinical value in determining patients who will eventually undergo spontaneous remission after uterine evacuation.
  • [MeSH-major] Hydatidiform Mole / enzymology. RNA. Telomerase / metabolism. Uterine Neoplasms / enzymology
  • [MeSH-minor] Adolescent. Adult. Chronic Disease. DNA-Binding Proteins. Female. Humans. Postoperative Care. Predictive Value of Tests. Pregnancy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11408866.001).
  • [ISSN] 0002-9378
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / telomerase RNA; 63231-63-0 / RNA; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


27. Liu CL, Wang YD, Jin XJ: [Clinical observation on treatment of non-small cell lung cancer with Chinese herbal medicine combined with bronchial arterial infusion chemotherapy]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2001 Aug;21(8):579-81
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical observation on treatment of non-small cell lung cancer with Chinese herbal medicine combined with bronchial arterial infusion chemotherapy].
  • OBJECTIVE: To explore the effect of treatment for non-small cell lung cancer (NSCLC) with Chinese herbal medicine (CHM) combined with bronchial arterial infusion chemotherapy (BAIC).
  • METHODS: Patients with moderate or advanced NSCLC were randomly divided into two groups, the 39 patients in the treated group treated with CHM plus BAIC therapy and 37 in the control group treated with BAIC alone.
  • The short-term therapeutic effect, long-term survival rate, changes of clinical principal symptoms, quality of life and peripheral blood pictures in the two groups were observed and compared.
  • RESULTS: After treatment the rate of CR + PR + NC in the treated and the control group was 92.31% and 70.27% respectively, the inter-group comparison showed a significant difference (P < 0.05).
  • CONCLUSION: Therapeutic effect of BAIC could be enhanced by combining it with CHM.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12575569.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 0 / Mitomycins; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


28. Sivanesaratnam V: Management of gestational trophoblastic disease in developing countries. Best Pract Res Clin Obstet Gynaecol; 2003 Dec;17(6):925-42
Genetic Alliance. consumer health - Gestational Trophoblastic Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In Malaysia, the incidence of molar pregnancy and gestational trophoblastic neoplasia is 2.8 and 1.59 per 1000 deliveries, respectively; the disease is more common among the Chinese compared to the Malays and Indians.
  • While uterine suction is the preferred method of uterine evacuation of hydatidiform mole, complete evacuation was not achieved at the first attempt in 25% of cases.
  • Partial moles comprise 30% of all moles; these need follow up similar to that for complete moles as they are potentially malignant.
  • In the management of invasive moles, chemotherapy should not be withheld in the presence of metastases or failure of regression of hCG.
  • Prophylactic hysterectomy and prophylactic chemotherapy are not recommended.
  • However, in those patients with unsatisfactory hCG regression curves indicating 'at risk' in developing gestational trophoblastic neoplasia (GTN), 'selective preventive chemotherapy' appears appropriate.
  • Chemotherapy remains the main modality of treatment for GTN.
  • [MeSH-major] Developing Countries. Gestational Trophoblastic Disease / therapy
  • [MeSH-minor] Antineoplastic Agents / adverse effects. Brain Neoplasms / secondary. Choriocarcinoma / prevention & control. Female. Humans. Hydatidiform Mole / surgery. Hydatidiform Mole, Invasive / therapy. Hysterectomy / methods. Jaundice / etiology. Pregnancy. Risk Factors. Trophoblastic Tumor, Placental Site / surgery. Uterine Neoplasms / prevention & control. Uterine Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14614890.001).
  • [ISSN] 1521-6934
  • [Journal-full-title] Best practice & research. Clinical obstetrics & gynaecology
  • [ISO-abbreviation] Best Pract Res Clin Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 33
  •  go-up   go-down


29. Berkowitz RS, Goldstein DP: Current management of gestational trophoblastic diseases. Gynecol Oncol; 2009 Mar;112(3):654-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: This review was undertaken to describe current understanding of the natural history of molar pregnancy and persistent gestational trophoblastic neoplasia (GTN) as well as recent advances in their management.
  • MATERIALS AND METHODS: Recent literature related to molar pregnancy and GTN was thoroughly analyzed to provide a comprehensive review of the current knowledge of their pathogenesis and treatment.
  • RESULTS: Studies in patients with familial recurrent molar pregnancy indicate that dysregulation of parentally imprinted genes is important in the pathogenesis of complete hydatidiform mole (CHM).
  • CHM is now being diagnosed earlier in pregnancy in the first trimester changing the clinical presentation and making the histologic appearance more similar to partial hydatidiform mole (PHM) and hydropic abortion.
  • While the classic presenting symptoms of CHM are less frequent, the risk of developing GTN remains unchanged.
  • Flow cytometry and immunostaining for maternally-expressed genes are helpful in distinguishing early CHM from PHM or hydropic abortion.
  • Patients with molar pregnancy have a low risk of developing persistent GTN after achieving even one non-detectable hCG level (hCG <5 mIU/ml).
  • Patients with high-risk metastatic GTN require aggressive combination chemotherapy in conjunction with surgery and radiation therapy to attain remission.
  • CONCLUSION: Our understanding of the natural history and management of molar pregnancy and GTN has advanced considerably in recent years.
  • While most patients can anticipate a high cure rate, efforts are still necessary to develop effective new second-line therapies for patients with drug-resistant disease.
  • [MeSH-major] Gestational Trophoblastic Disease / therapy
  • [MeSH-minor] Female. Humans. Hydatidiform Mole / pathology. Hydatidiform Mole / therapy. Pregnancy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18851873.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 149
  •  go-up   go-down


30. Kerkmeijer L, Wielsma S, Bekkers R, Pyman J, Tan J, Quinn M: Guidelines following hydatidiform mole: a reappraisal. Aust N Z J Obstet Gynaecol; 2006 Apr;46(2):112-8
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Guidelines following hydatidiform mole: a reappraisal.
  • OBJECTIVE: The aim of this study was to determine how often patients with complete hydatidiform mole (CHM) who spontaneously achieve normal human chorionic gonadotrophin (hCG) levels subsequently develop persistent or recurrent gestational trophoblast disease.
  • METHODS: Four hundred and fourteen cases of CHM registered at the Hydatidiform Mole Registry of Victoria were reviewed retrospectively after molar evacuation.
  • Maternal age, gestational age, gravidity and parity were determined for each patient, as well as the need for chemotherapy.
  • RESULTS: Among the 414 patients, 55 (13.3%) required chemotherapy for persistent trophoblastic disease.
  • None of the patients whose hCG levels spontaneously fell to normal subsequently developed persistent molar disease.
  • [MeSH-major] Chorionic Gonadotropin / blood. Hydatidiform Mole / diagnosis. Neoplasm Recurrence, Local / diagnosis. Practice Guidelines as Topic. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Adult. Biomarkers, Tumor / blood. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Hysterectomy / methods. Maternal Age. Monitoring, Physiologic / standards. Parity. Pregnancy. Pregnancy Complications, Neoplastic / diagnosis. Pregnancy Complications, Neoplastic / therapy. Pregnancy Outcome. Registries. Retrospective Studies. Risk Assessment. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Hydatidiform mole.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Aust N Z J Obstet Gynaecol. 2006 Jun;46(3):179. Wiesma, Sabien [corrected to Wielsma, Sabien]
  • (PMID = 16638032.001).
  • [ISSN] 0004-8666
  • [Journal-full-title] The Australian & New Zealand journal of obstetrics & gynaecology
  • [ISO-abbreviation] Aust N Z J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chorionic Gonadotropin
  •  go-up   go-down


36. Chen HY, Lu HF, Yang JS, Kuo SC, Lo C, Yang MD, Chiu TH, Chueh FS, Ho HC, Ko YC, Chung JG: The novel quinolone CHM-1 induces DNA damage and inhibits DNA repair gene expressions in a human osterogenic sarcoma cell line. Anticancer Res; 2010 Oct;30(10):4187-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The novel quinolone CHM-1 induces DNA damage and inhibits DNA repair gene expressions in a human osterogenic sarcoma cell line.
  • 20-Fluoro-6,7-methylenedioxy-2-phenyl-4-quino-lone (CHM-1) has been reported to induce cell cycle arrest and apoptosis in many types of cancer cells.
  • However, there is no available information to show CHM-1 affecting DNA damage and expression of associated repair genes.
  • Herein, we investigated whether or not CHM-1 induced DNA damage and affected DNA repair gene expression in U-2 OS human osterogenic sarcoma cells.
  • The comet assay showed that incubation of U-2 OS cells with 0, 0.75, 1.5, 3 and 6 μM of CHM-1 led to a longer DNA migration smear (comet tail).
  • DNA gel electrophoresis showed that 3 μM of CHM-1 for 24 and 48 h treatment induced DNA fragmentation in U-2 OS cells.
  • Real-time PCR analysis showed that treatment with 3 μM of CHM-1 for 24 h reduced the mRNA expression levels of ataxia telangiectasia mutated (ATM), ataxia-telangiectasia and Rad3-related (ATR), breast cancer 1, early onset (BRCA1), 14-3-3sigma (14-3-3σ), DNA-dependent serine/threonine protein kinase (DNA-PK) and O(6)-methylguanine-DNA methyltransferase (MGMT) genes in a time-dependent manner.
  • Taken together, the results indicate that CHM-1 caused DNA damage and reduced DNA repair genes in U-2 OS cells, which may be the mechanism for CHM-1-inhibited cell growth and induction of apoptosis.
  • [MeSH-major] Bone Neoplasms / drug therapy. DNA Damage. DNA Repair / drug effects. Dioxoles / pharmacology. Osteosarcoma / drug therapy. Quinolones / pharmacology
  • [MeSH-minor] 14-3-3 Proteins / biosynthesis. 14-3-3 Proteins / genetics. Ataxia Telangiectasia Mutated Proteins. BRCA1 Protein / biosynthesis. BRCA1 Protein / genetics. Biomarkers, Tumor / biosynthesis. Biomarkers, Tumor / genetics. Cell Cycle Proteins / biosynthesis. Cell Cycle Proteins / genetics. Cell Line, Tumor. Comet Assay. DNA Fragmentation / drug effects. DNA Modification Methylases / biosynthesis. DNA Modification Methylases / genetics. DNA Repair Enzymes / biosynthesis. DNA Repair Enzymes / genetics. DNA-Activated Protein Kinase / biosynthesis. DNA-Activated Protein Kinase / genetics. DNA-Binding Proteins / biosynthesis. DNA-Binding Proteins / genetics. Exonucleases / biosynthesis. Exonucleases / genetics. Exoribonucleases. Gene Expression / drug effects. Humans. Protein-Serine-Threonine Kinases / biosynthesis. Protein-Serine-Threonine Kinases / genetics. Tumor Suppressor Proteins / biosynthesis. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21036739.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / 14-3-3 Proteins; 0 / 2'-fluoro-6,7-methylenedioxy-2-phenyl-4-quinolone; 0 / BRCA1 Protein; 0 / BRCA1 protein, human; 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Dioxoles; 0 / Quinolones; 0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / ATR protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / DNA-Activated Protein Kinase; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 3.1.- / Exonucleases; EC 3.1.- / Exoribonucleases; EC 3.1.- / SFN protein, human; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


37. Lichtenberg ES: Gestational trophoblastic tumor after medical abortion. Obstet Gynecol; 2003 May;101(5 Pt 2):1137-9
Hazardous Substances Data Bank. MIFEPRISTONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pretreatment ultrasound was consistent with an abnormal pregnancy.
  • Passage of tissue ensued after mifepristone-misoprostol administration.
  • Sixty days after initial treatment, she presented to a hospital with a history of intermittent bleeding and underwent curettage, revealing a complete hydatidiform mole.
  • Chemotherapy was instituted when levels of hCG plateaued.
  • Complete hCG regression occurred after three weekly injections of methotrexate, and postmolar surveillance is uneventful to date.
  • [MeSH-major] Abortifacient Agents, Steroidal / adverse effects. Abortion, Therapeutic / adverse effects. Gestational Trophoblastic Disease / diagnosis. Mifepristone / adverse effects. Misoprostol / adverse effects. Oxytocics / adverse effects
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Female. Humans. Methotrexate / therapeutic use. Pregnancy. Pregnancy Trimester, First

  • MedlinePlus Health Information. consumer health - Abortion.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. MISOPROSTOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12738129.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Abortifacient Agents, Steroidal; 0 / Antineoplastic Agents; 0 / Oxytocics; 0E43V0BB57 / Misoprostol; 320T6RNW1F / Mifepristone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


38. Kohorn EI: Measurement of CA-125 in trophoblastic disease. Gynecol Oncol; 2000 Jul;78(1):39-42
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Physicians treating hydatidiform mole are still seeking means of identifying those patients who will require chemotherapy.
  • CA-125 was measured at the time of hydatidiform mole evacuation to determine (1) whether it would predict the need for chemotherapy and (2) whether it correlated with human chorionic gonadotropin and tumor load in following patients with hydatidiform mole and metastatic gestational trophoblastic disease.
  • Sixteen patients had hydatidiform mole with spontaneous resolution, fourteen had nonmetastatic gestational trophoblastic tumor, and four had low-risk metastatic disease.
  • Ten patients had partial hydatidiform mole and one of these required chemotherapy.
  • RESULTS: The mean preevacuation CA-125 among the 15 patients with complete hydatidiform mole was 40.9 U/ml: 52.5 U/ml for 5 patients who required chemotherapy and 36.2 U/ml for 10 patients who did not require chemotherapy.
  • In nine patients with partial hydatidiform mole CA-125 was elevated prior to mole evacuation and then became negative.
  • The patient with a tetraploid conceptus who required chemotherapy had negative CA-125.
  • [MeSH-major] Biomarkers, Tumor / analysis. CA-125 Antigen / analysis. Hydatidiform Mole / immunology. Uterine Neoplasms / immunology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chorionic Gonadotropin / analysis. False Negative Reactions. Female. Humans. Predictive Value of Tests. Pregnancy. Reproducibility of Results

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Academic Press.
  • (PMID = 10873407.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Chorionic Gonadotropin
  •  go-up   go-down


39. Chou LC, Yang JS, Huang LJ, Wu HC, Lu CC, Chiang JH, Chen KT, Kuo SC, Chung JG: The synthesized 2-(2-fluorophenyl)-6,7-methylenedioxyquinolin-4-one (CHM-1) promoted G2/M arrest through inhibition of CDK1 and induced apoptosis through the mitochondrial-dependent pathway in CT-26 murine colorectal adenocarcinoma cells. J Gastroenterol; 2009;44(10):1055-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The synthesized 2-(2-fluorophenyl)-6,7-methylenedioxyquinolin-4-one (CHM-1) promoted G2/M arrest through inhibition of CDK1 and induced apoptosis through the mitochondrial-dependent pathway in CT-26 murine colorectal adenocarcinoma cells.
  • BACKGROUND: In this study, we investigated the effects of 2-(2-fluorophenyl)-6,7-methylenedioxyquinolin-4-one (CHM-1) on cell viability, cell cycle arrest and apoptosis in CT-26 murine colorectal adenocarcinoma cells.
  • CHM-1 promoted G2/M arrest by PI staining and flow cytometric analysis.
  • The in vivo anti-tumor effects of CHM-1-P were evaluated in BALB/c mice inoculated with CT-26 cells orthotopic model.
  • RESULTS: CHM-1 induced CT-26 cell viability inhibition and morphologic changes in a dose-dependent and time-dependent manner and the approximate IC50 was 742.36 nM.
  • CHM-1 induced significant G2/M arrest and apoptosis in CT-26 cells.
  • CHM-1 inhibited the CDK1 activity and decreased CDK1, Cyclin A, Cyclin B protein levels.
  • CHM-1 induced apoptosis in CT-26 cells and promoted increasing of cytosolic cytochrome c, AIF, Bax, BAD, cleavage of pro-caspase-9, and -3.
  • The significant reduction of caspase-9 and -3 activity and increasing the viable CT-26 cells after pretreated with caspase-9 and -3 inhibitor indicated that CHM-1-induced apoptosis was mainly mediated a mitochondria-dependent pathway.
  • CHM-1-P improved mice survival rate, and enlargement of the spleen and liver metastasis were significantly reduced in groups treated with either 10 mg/kg and 30 mg/kg of CHM-1-P and 5-FU in comparison to these of CT-26/BALB/c mice.
  • CONCLUSIONS: Taken together, CHM-1 acted against colorectal adenocarcinoma cells in vitro via G2/M arrest and apoptosis, and CHM-1-P inhibited tumor growth in vivo.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / pharmacology. Apoptosis / drug effects. CDC2 Protein Kinase / antagonists & inhibitors. Cell Cycle / drug effects. Cell Survival / drug effects. Colorectal Neoplasms / drug therapy. Dioxoles / pharmacology. Quinolones / pharmacology
  • [MeSH-minor] Animals. Caspase 3 / metabolism. Caspase 9 / metabolism. Cell Division / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Cyclin A / drug effects. Cyclin A / metabolism. Cyclin B / drug effects. Cyclin B / metabolism. Dose-Response Relationship, Drug. Flow Cytometry. G2 Phase / drug effects. Humans. Liver Neoplasms / secondary. Meiosis. Mice. Mice, Inbred BALB C. Mitochondria / drug effects. Mitochondria / metabolism. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Food Chem Toxicol. 2009 Jan;47(1):171-9 [19038304.001]
  • [Cites] Mol Cancer Ther. 2008 Feb;7(2):350-60 [18281518.001]
  • [Cites] Cancer Lett. 2007 Nov 8;257(1):87-96 [17689859.001]
  • [Cites] Anticancer Res. 2004 May-Jun;24(3a):1769-78 [15274354.001]
  • [Cites] Int J Pharm. 2008 Jun 5;357(1-2):139-47 [18329194.001]
  • [Cites] Anticancer Res. 2008 Mar-Apr;28(2A):833-42 [18507026.001]
  • [Cites] Eur J Nutr. 2008 May;47 Suppl 2:73-88 [18458837.001]
  • [Cites] J Pharm Sci. 2008 Sep;97(9):4011-9 [18240304.001]
  • (PMID = 19688288.001).
  • [ISSN] 1435-5922
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / 2'-fluoro-6,7-methylenedioxy-2-phenyl-4-quinolone; 0 / Antineoplastic Agents; 0 / Cyclin A; 0 / Cyclin B; 0 / Dioxoles; 0 / Quinolones; EC 2.7.11.22 / CDC2 Protein Kinase; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 9
  •  go-up   go-down


40. Zhao J, Xiang Y, Wan XR, Feng FZ, Cui QC, Yang XY: Molecular genetic analyses of choriocarcinoma. Placenta; 2009 Sep;30(9):816-20
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The genetic origin, immunogenicity, sensitivity to chemotherapy and prognosis of these two kinds of conditions are quite different, so identification of these two kinds of choriocarcinoma is of great importance.
  • The objective of this study is to distinguish choriocarcinoma as gestational or non-gestational and identify the causative pregnancy of gestational choriocarcinoma through molecular genetic analysis.
  • METHODS: Twelve patients with choriocarcinoma, who had experienced surgery prior to chemotherapy, were enrolled in this study.
  • In order to prepare DNA from choriocarcinoma tissue, areas of choriocarcinoma were firstly microdissected from haematoxylin and eosin-stained sections.
  • PCR amplification and fluorescent microsatellite genotyping were performed using DNA from the couples and captured tissue.
  • The remaining eight cases were all gestational in origin and the causative pregnancies were identified as AnCHM (androgenetic complete hydatidiform mole) in six and normal pregnancies in two respectively.
  • CONCLUSION: Microsatellite polymorphism analysis is a molecular approach for distinguishing the non-gestational choriocarcinoma from the gestational one, and can also be used to identify the causative pregnancy of gestational choriocarcinoma.
  • Antecedent pregnancy prior to choriocarcinoma is not always its causative pregnancy.
  • Therefore, it is reasonable to identify the causative pregnancy by its genetic origin, instead of clinical impression.
  • [MeSH-major] Choriocarcinoma, Non-gestational / genetics. Gestational Trophoblastic Disease / genetics. Hydatidiform Mole / genetics. Uterine Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Alleles. DNA / blood. Diagnosis, Differential. Female. Genotype. Humans. Microsatellite Instability. Pregnancy. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Young Adult

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19647314.001).
  • [ISSN] 1532-3102
  • [Journal-full-title] Placenta
  • [ISO-abbreviation] Placenta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 9007-49-2 / DNA
  •  go-up   go-down


41. Hancock BW, Nazir K, Everard JE: Persistent gestational trophoblastic neoplasia after partial hydatidiform mole incidence and outcome. J Reprod Med; 2006 Oct;51(10):764-6
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistent gestational trophoblastic neoplasia after partial hydatidiform mole incidence and outcome.
  • OBJECTIVE: To report the Sheffield experience with persistent gestational trophoblastic neoplasia (GTN) after partial hydatidiform mole (PHM) and to review worldwide experience.
  • Clinical features, treatment and outcome were recorded.
  • Forty-one developed persistent GTN.
  • During the same period, 271 cases of persistent GTN originally registered as complete hydatidiform mole were reviewed; 3 were found to be PHMs (2 low, 1 high risk).
  • In all, 15 of 17 persistent PHMs required chemotherapy.
  • CONCLUSION: Persistent GTN requiring chemotherapy can occasionally occur after PHM; surveillance of all cases continues to be recommended.
  • [MeSH-major] Hydatidiform Mole / epidemiology. Neoplasm Recurrence, Local / epidemiology. Uterine Neoplasms / epidemiology
  • [MeSH-minor] England / epidemiology. Female. Humans. Incidence. Medical Records. Pregnancy. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Hydatidiform mole.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17086803.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Allmer C, Ventegodt S, Kandel I, Merrick J: Positive effects, side effects, and adverse events of clinical holistic medicine. A review of Gerda Boyesen's nonpharmaceutical mind-body medicine (biodynamic body-psychotherapy) at two centers in the United Kingdom and Germany. Int J Adolesc Med Health; 2009 Jul-Sep;21(3):281-97
MedlinePlus Health Information. consumer health - Mental Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To review adverse events of intensive, clinical holistic medicine (CHM) as it is practiced in holistic body-psychotherapy in England and Germany.
  • Gerda Boyesen's "biodynamic body-psychotherapy" (BBP) is an intensive type of holistic mind-body medicine used by Boyesen at two centers.
  • The first author worked closely with Boyesen 1995-2005 with full insight in all aspects of the therapy and provided the data on side-effects.
  • RESULTS: Therapy helped chronic patients with physical, psychological, sexual, psychiatric and existential problems to improve health, ability, and quality of life (NNT (number needed to treat) = 1-3).
  • Effective in the treatment of mentally ill patients (schizophrenia, anxiety, poor mental health, low general ability).
  • For retraumatization, brief reactive psychosis, depression, depersonalization and derealization, implanted memories, side effects from manipulations of the body, suicide/suicide attempts, hospitalization for physical and mental health problem during or 90 days after treatment, NNH (number needed to harm) > 13,500.
  • INTERPRETATION: Intensive, holistic non-drug medicine is helpful for physical, sexual, psychological, psychiatric and existential problems and is completely safe for the patient.
  • The therapeutic value TV = NNH/NNT > 5,000.
  • Altogether about 18,000 patients treated with different subtypes of CHM in four different countries have now been evaluated for effects, side effects and adverse events, with similar results.
  • [MeSH-major] Holistic Health. Mental Disorders / therapy. Mind-Body Therapies. Psychotherapy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20014632.001).
  • [ISSN] 0334-0139
  • [Journal-full-title] International journal of adolescent medicine and health
  • [ISO-abbreviation] Int J Adolesc Med Health
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


43. Chen Z, Gu K, Zheng Y, Zheng W, Lu W, Shu XO: The use of complementary and alternative medicine among Chinese women with breast cancer. J Altern Complement Med; 2008 Oct;14(8):1049-55
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Using data from the Shanghai Breast Cancer Survival Study (SBCSS), we estimated the prevalence and perceived benefits of complementary and alternative medicine (CAM) and Chinese herbal medicine (CHM), and relevant demographic and clinical factors.
  • Ninety-seven percent (97%) of participants used CAM therapy after diagnosis.
  • Supplements were the most common type, followed by CHM, and physical activity.
  • Walking was the most popular type of physical activity.
  • Almost all CHM users used CHM as part of their cancer treatment; three quarters reported CHM use for boosting the immune system.
  • About two thirds of women considered CHM effective.
  • CHM use was associated with younger age, higher income, menopausal symptoms, completion of chemotherapy, and past tamoxifen use.
  • Patients with an earlier clinical stage or who had undergone radiotherapy used less CHM.
  • Chemotherapy or radiotherapy and cancer metastasis were positively related to physical activity participation.
  • CONCLUSIONS: Given the high prevalence of CAM use in patients with breast cancer and the variety of types of CAM, more research is needed to determine the impact of CAM's effectiveness and safety and interaction with conventional cancer treatment on breast cancer survival.
  • [MeSH-major] Attitude to Health. Breast Neoplasms / epidemiology. Breast Neoplasms / therapy. Complementary Therapies / utilization. Patient Satisfaction / statistics & numerical data. Women's Health
  • [MeSH-minor] Adult. Aged. China / epidemiology. Cohort Studies. Combined Modality Therapy. Cross-Sectional Studies. Female. Humans. Middle Aged. Motivation. Prevalence. Quality of Life. Socioeconomic Factors. Surveys and Questionnaires


44. Flower A, Lewith GT, Little P: Seeking an oracle: using the Delphi process to develop practice guidelines for the treatment of endometriosis with Chinese herbal medicine. J Altern Complement Med; 2007 Nov;13(9):969-76
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Seeking an oracle: using the Delphi process to develop practice guidelines for the treatment of endometriosis with Chinese herbal medicine.
  • OBJECTIVES: To use a modified Delphi to develop good practice guidelines for a feasibility study exploring the role of Chinese herbal medicine (CHM) in the treatment of endometriosis.
  • DESIGN: An expert group was convened for a three-round Delphi that initially produced key statements relating to the CHM diagnosis and treatment of endometriosis (round 1) and then anonymously rated these on a 1-7 Likert scale (rounds 2 and 3).
  • RESULTS: Consensus (good practice) guidelines for the CHM treatment of endometriosis relating to common diagnostic patterns, herb selection, dosage, and patient management were produced.
  • CONCLUSIONS: In the absence of rigorous evidence, Delphi offers a way to synthesize expert knowledge relating to diagnosis, patient management, and herbal selection in the treatment of endometriosis.
  • The limitations of the expert group and the inability of Delphi to capture the subtle nuances of individualized clinical decision-making limit the usefulness of this approach.
  • [MeSH-major] Delphi Technique. Drugs, Chinese Herbal / therapeutic use. Endometriosis / drug therapy. Medicine, Chinese Traditional / instrumentation. Phytotherapy / methods. Practice Guidelines as Topic

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18047443.001).
  • [ISSN] 1075-5535
  • [Journal-full-title] Journal of alternative and complementary medicine (New York, N.Y.)
  • [ISO-abbreviation] J Altern Complement Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal
  •  go-up   go-down


45. Schoeberl MR: A model for the behavior of beta-hCG after evacuation of hydatidiform moles. Gynecol Oncol; 2007 Jun;105(3):776-9
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A model for the behavior of beta-hCG after evacuation of hydatidiform moles.
  • OBJECTIVES: The objective of this study is to develop a physical model of the behavior of beta-hCG following the complete evacuation of a hydatidiform mole.
  • Because hCG is an excellent marker for continued trophoblastic activity, the model can be used for early detection of persistent sites.
  • METHOD: The model was developed from analysis of the post surgical hCG decrease in a patient with Stage III gestational trophoblastic neoplasia.
  • As found in previous molar pregnancy studies, hCG follows a log-linear decrease after resolution.
  • In contrast to those studies, however, we assume that the decrease can be explained by the dilution of the residual hCG from two different tissue reservoirs, a tissue reservoir with a half-life of approximately 4 days and a reservoir with a longer half-life, in this case approximately 18 days.
  • RESULTS: Simple dilution of two tissue reservoirs explains behavior of hCG following tumor removal.
  • The model also explains the hCG decrease in a larger study of Japanese and Dutch women following the evacuation of uneventful hydatidiform moles.
  • CONCLUSIONS: Following an initial rapid drop in hCG after resolution of the mole, the patient should experience a slower drop associated with the dilution of residual hCG in the deep tissue reservoir.
  • The physical model suggests that even earlier detection of chemotherapy resistant persistent trophoblastic disease is possible if the patient's decrease in hCG is slower than a log-linear fit to the patient's previous data.
  • [MeSH-major] Chorionic Gonadotropin, beta Subunit, Human / metabolism. Hydatidiform Mole / metabolism. Models, Biological. Uterine Neoplasms / metabolism
  • [MeSH-minor] Female. Humans. Middle Aged. Pregnancy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17395254.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human
  •  go-up   go-down


46. Niemann I, Hansen ES, Sunde L: The risk of persistent trophoblastic disease after hydatidiform mole classified by morphology and ploidy. Gynecol Oncol; 2007 Feb;104(2):411-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The risk of persistent trophoblastic disease after hydatidiform mole classified by morphology and ploidy.
  • OBJECTIVE: Hydatidiform mole can be classified by histopathologic characteristics and by genetic constitutions and most complete moles are diploid, whereas most partial moles are triploid.
  • We investigated the concordance between these two classifications, characterized moles with conflicting classifications, and compared the ability of the two classifications to discriminate between patients with and without a substantial risk of persistent trophoblastic disease.
  • METHODS: 294 cases of consecutively collected hydropic placentas clinically suspected of hydatidiform mole made the basis of this retrospective study.
  • Data on possible chemotherapy were collected for each patient.
  • RESULTS: 270 of the conceptuses were histopathologically classified as hydatidiform mole.
  • Among the 24 conceptuses classified as non-molar miscarriage, 20 were triploids, 2 were diploid androgenetic and 2 were diploid biparental.
  • 5% of the patients with hydropic placentas classified as partial mole encountered persistent trophoblastic disease; however, the genome was diploid in all these moles.
  • CONCLUSION: As full concordance between the histopathologic and the genetic classifications was not found, we believe that features beyond the genetic constitution influence the development of morphologic features in hydatidiform moles.
  • We recommend that gestations suspected of hydatidiform mole are subjected to histopathologic examination.
  • If hydatidiform change and trophoblastic hyperplasia are identified, the ploidy should be used to identify patients with a high risk of persistent trophoblastic disease.
  • [MeSH-major] Hydatidiform Mole / genetics. Hydatidiform Mole / pathology. Ploidies. Trophoblastic Neoplasms / genetics. Trophoblastic Neoplasms / pathology. Uterine Neoplasms / genetics. Uterine Neoplasms / pathology
  • [MeSH-minor] Animals. Chickens. Choriocarcinoma / drug therapy. Choriocarcinoma / genetics. Choriocarcinoma / pathology. Female. Humans. Pregnancy. Retrospective Studies. Trout

  • Genetic Alliance. consumer health - Hydatidiform mole.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17011616.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Wu Y, Li JC, Mao LG: [Study of Chinese herbal medicine in treating ascites and their mechanism in regulating lymphatic stomata]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2001 Sep;21(9):677-9
Hazardous Substances Data Bank. NITRIC OXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To study the therapeutic effect of Chinese herbal medicines (CHM) in treating ascites to elucidate its mechanism in regulating the lymphatic stomata and promoting the absorption of ascites from the peritoneal cavity.
  • METHODS: Using scanning electron microscope (SEM) and computerized image processing and quantitative analysis assays, the CHM extract consisting of Atractylodes macrocephala, Salvia miltiorrhiza, Codonopsis pilosula, Alismatis orientale and Leonurus heterophyllus were studied.
  • RESULTS: Intraperitoneal injection of nitric oxide (NO) supplier or CHM administration could cause the average area of lymphatic stomata obviously enlarged (P < 0.05), and the open numbers significantly increased (P < 0.01) in normal healthy mice.
  • When L-notroarginine, a NO synthetase suppressor, was injected after CHM administration, it was found that the regulating effect of CHM on lymphatic stomata was inverted obviously, i.e. the average area and the density of lymphatic stomata were markedly reduced (P < 0.01).
  • CONCLUSION: CHM might treat ascites through increasing the endogenous NO concentration to open the lymphatic stomata and in turn to conduct the peritoneal water through lymphatic path.

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12575556.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 31C4KY9ESH / Nitric Oxide; EC 1.14.13.39 / Nitric Oxide Synthase
  •  go-up   go-down


48. Ruan XM, Jiang W, Lin Y: [Clinical efficacy of treatment for regulating Pi and protecting Xin in treating patients after coronary artery bypass grafting and its effect on patients' quality of life]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2006 Jan;26(1):28-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical efficacy of treatment for regulating Pi and protecting Xin in treating patients after coronary artery bypass grafting and its effect on patients' quality of life].
  • OBJECTIVE: To evaluate the clinical efficacy of treatment for regulating Pi and protecting Xin (abbr. as CHM) and its effect on quality of life (QOL) in patients after coronary artery bypass grafting (CABG).
  • METHODS: One hundred and six patients, who were planned to undergo CABG were assigned into two groups, the 51 patients in the control group were treated with conventional Western medicinal treatment (WM) and the 55 patients in the experimental group were treated by WM with additional medication of CHM constituted mainly by modified Huxin Recipe.
  • CONCLUSION: Treatment for regulating Pi and protecting Xin by modified Huxin Recipe can improve the recovery process of patients after CABG, elevate patients' heart function, symptoms and QOL.


49. Dong JC, Ni J, Gong ZH: [Experimental study on prevention and treatment of bronchial asthma by compound Chinese herbal monomer recipe]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2004 Aug;24(8):717-21
MedlinePlus Health Information. consumer health - Asthma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Experimental study on prevention and treatment of bronchial asthma by compound Chinese herbal monomer recipe].
  • OBJECTIVE: To observe the effect of compound Chinese herbal monomer (CHM) recipe, consisted of ligustrazin (3.75 mg/kg x d), baicalin (7.5 mg/kg x d) and ginkgolide (2 mg/kg x d), on airway atopic inflammation and hyper-responsiveness in asthma.
  • METHODS: Model guinea pigs of asthma were randomly divided into three groups, the model group, the CHM group and the cromlyn sodium (CS) group, they were treated by atomizing inhalation with normal saline, CHM and CS respectively.
  • And the effect of treatment on the airway hyperresponsiveness and pathology among groups were compared.
  • RESULTS: CHM showed significant inhibition on blood eosinophil count and BALF and total cell count in BALF, showing significant difference (P < 0.05 or P < 0.01) as compared with those in the model group.
  • Airway responsiveness determination showed that CHM has significant inhibitory action on it.
  • And the pathology of airway inflammation in the CHM group was significantly milder than that in the model group.
  • CONCLUSION: The compound inhalation liquid consisted of ligustrazin, baicalin and ginkgolide, has the anti-asthmatic airway atopic inflammation and depression on airway hyper-responsiveness, suggesting that components of compound CHM recipe could inhibit the multiple pathogenetic asthmatic inflammation from different angles and on multiple targets, so as to cure asthma effectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15366597.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Anti-Asthmatic Agents; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Drugs, Chinese Herbal; 0 / Flavonoids; 0 / Pyrazines; 347Q89U4M5 / baicalin; V80F4IA5XG / tetramethylpyrazine
  •  go-up   go-down


50. Gillespie AM, Kumar S, Hancock BW: Treatment of persistent trophoblastic disease later than 6 months after diagnosis of molar pregnancy. Br J Cancer; 2000 Apr;82(8):1393-5
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of persistent trophoblastic disease later than 6 months after diagnosis of molar pregnancy.
  • Of 4257 patients with gestational trophoblastic disease (GTD) registered between 1986 and 1996 with the Trophoblastic Screening and Treatment Centre, Sheffield, 231 women required chemotherapy; 28 were treated 24 weeks or more after the initial evacuation of products of conception.
  • In 18 patients late treatment was a result of a predetermined watch and wait policy on the part of the Centre; these patients formed the study group.
  • The time interval from first evacuation (diagnosis) to start of chemotherapy was calculated for each patient.
  • Hospital records were reviewed when the interval of observation was 24 weeks or greater to determine patient characteristics, treatment and outcome.
  • The interval from diagnosis to treatment ranged from 24 to, in one case, 56 weeks (median 33 weeks).
  • Fourteen of 18 women had complete moles, 3/18 had partial moles and one had unclassified disease.
  • All women had low-risk disease and were treated with single-agent methotrexate; 17 were cured with this regimen, one also required salvage chemotherapy.
  • In conclusion, where a successful surveillance programme is in operation for GTD, a wait and watch policy can be adopted without compromising patients whose definitive treatment is commenced more than 6 months after the initial diagnosis.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hydatidiform Mole / surgery. Methotrexate / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Trophoblastic Neoplasms / drug therapy. Uterine Neoplasms / drug therapy. Uterine Neoplasms / surgery
  • [MeSH-minor] Adult. Dactinomycin / administration & dosage. Databases as Topic. England. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Leucovorin / therapeutic use. Middle Aged. Pregnancy. Prognosis. Registries. Salvage Therapy. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 Nov;81(6):1037-41 [10576662.001]
  • [Cites] Cancer. 1976 Sep;38(3):1373-85 [182354.001]
  • [Cites] Br J Cancer. 1997;76(10):1382-6 [9374387.001]
  • [Cites] Int J Androl. 1987 Feb;10(1):389-92 [2438231.001]
  • [Cites] J Clin Oncol. 1996 Oct;14(10):2769-73 [8874338.001]
  • [Cites] Am J Obstet Gynecol. 1983 Mar 1;145(5):591-5 [6829636.001]
  • (PMID = 10780516.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] SCOTLAND
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 1CC1JFE158 / Dactinomycin; 6PLQ3CP4P3 / Etoposide; Q573I9DVLP / Leucovorin; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ PMC2363366
  •  go-up   go-down


51. Sebire NJ, Lindsay I: Current issues in the histopathology of gestational trophoblastic tumors. Fetal Pediatr Pathol; 2010;29(1):30-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gestational trophoblastic neoplasia (GTN) encompasses several entities including complete (CHM) and partial (PHM) hydatidiform mole (HM) and the malignant gestational trophoblastic tumors (GTTs), choriocarcinoma (CC), and placental-site trophoblastic tumor (PSTT), including epithelioid trophoblastic tumor (ETT).
  • With such a protocol, many cases of pGTN are identified early at a presymptomatic stage based on plateuing or rising hCG concentrations and subsequently treated successfully with chemotherapy.
  • However, PSTTs, represent malignant differentiation toward implantation-site type trophoblast, with lower hCG levels and less response to chemotherapy.
  • [MeSH-minor] Female. Humans. Pregnancy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20055562.001).
  • [ISSN] 1551-3823
  • [Journal-full-title] Fetal and pediatric pathology
  • [ISO-abbreviation] Fetal Pediatr Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 47
  •  go-up   go-down


52. Cheng CW, Bian ZX, Wu TX: Systematic review of Chinese herbal medicine for functional constipation. World J Gastroenterol; 2009 Oct 21;15(39):4886-95
PubMed Health. DARE review .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Many patients are disappointed by current conventional treatments and, therefore, seek help from complementary and alternative medicine (CAM).
  • Although there are many Chinese herbal medicine (CHM) interventions available, and some have been verified by clinical trials, their efficacy and safety are still questioned by both patients and health care providers worldwide.
  • Second, the benefits of individual CHM interventions or individual types of CHM intervention for the treatment of functional constipation are analyzed.
  • [MeSH-major] Constipation / drug therapy. Drugs, Chinese Herbal / therapeutic use. Gastrointestinal Agents / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Evidence-Based Medicine. Humans. Infant. Middle Aged. Randomized Controlled Trials as Topic. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Constipation.
  • MedlinePlus Health Information. consumer health - Constipation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pharmacol Exp Ther. 2003 Aug;306(2):787-93 [12724347.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Aug 1;18(3):319-26 [12895216.001]
  • [Cites] Adolesc Med Clin. 2004 Feb;15(1):37-52 [15272255.001]
  • [Cites] Am J Gastroenterol. 2005 Apr;100(4):936-71 [15784043.001]
  • [Cites] J Manag Care Pharm. 2008 Nov;14(9 Suppl A):1-15 [18950252.001]
  • [Cites] PLoS One. 2008;3(2):e1610 [18286168.001]
  • [Cites] N Engl J Med. 2008 May 29;358(22):2344-54 [18509121.001]
  • [Cites] BMC Complement Altern Med. 2008;8:46 [18652682.001]
  • [Cites] Aliment Pharmacol Ther. 2007 Jul 15;26(2):237-48 [17593069.001]
  • (PMID = 19842218.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 0 / Gastrointestinal Agents
  • [Number-of-references] 78
  • [Other-IDs] NLM/ PMC2764965
  •  go-up   go-down


53. Su Y, Sun Y, Ma L: [Observation on treatment of ectopic pregnancy by combination therapy of Chinese herbal medicine with mifepristone or methotrexate]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2002 Jun;22(6):417-9
Hazardous Substances Data Bank. MIFEPRISTONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Observation on treatment of ectopic pregnancy by combination therapy of Chinese herbal medicine with mifepristone or methotrexate].
  • OBJECTIVE: To find a simpler, effectiver with less side-effect method for treatment of ectopic pregnancy.
  • METHODS: One hundred and fourteen patients of ectopic pregnancy were divided into two groups, the 56 patients in Group A were treated with Mifepristone and Chinese herbal medicine (CHM), and 58 patients in Group B were treated with Methotrexate and CHM.
  • The therapeutic effect in both groups was observed and compared.
  • Time for successful treatment was 14.54 +/- 5.87 days in Group A and 9.00 +/- 5.09 days in Group B, comparison of them showed significant difference (P < 0.01).
  • Insignificance revealed in comparison between the occurrence of side-effects for the groups, such as nausea, vomiting, diarrhea, liver dysfunction and lowering of white blood cells, but significance was shown in re-menstruation time (43.43 +/- 1.77 days vs 38.38 +/- 1.13 days, P < 0.05).
  • CONCLUSION: Treatments of combined CHM with Mifepristone or Methotrexate showed similar therapeutic effect in treating ectopic pregnancy, but the latter showed a quicker initiation and less side-effects in delaying the re-menstruation time.

  • Genetic Alliance. consumer health - Ectopic Pregnancy.
  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ectopic Pregnancy.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12585183.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Abortifacient Agents; 0 / Drugs, Chinese Herbal; 320T6RNW1F / Mifepristone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


54. Shu J, Miao P, Wang RJ: [Clinical observation on effect of Chinese herbal medicine plus human chorionic gonadotropin and progesterone in treating anticardiolipin antibody-positive early recurrent spontaneous abortion]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2002 Jun;22(6):414-6
Hazardous Substances Data Bank. PROGESTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To find a method without corticosteroids, aspirin or heparin for treatment of anticardiolipin antibody-positive early recurrent spontaneous abortion (AARSA).
  • METHODS: Twenty-three patients of AARSA in the treated group were treated with Chinese herbal medicine (CHM) plus human chorionic gonadotropin and progesterone, and 18 patiens in the control group were treated with multi-vitamin only.
  • RESULTS: After treatment, anticardiolipin antibody negative converted in 20 cases (86.9%) of the treated group.
  • CONCLUSION: CHM plus human chorionic gonadotropin and progesterone could cure AARSA effectively.

  • Genetic Alliance. consumer health - Recurrent spontaneous abortion.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12585182.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Anticardiolipin; 0 / Chorionic Gonadotropin; 0 / Drugs, Chinese Herbal; 4G7DS2Q64Y / Progesterone
  •  go-up   go-down


55. Matsui H, Iitsuka Y, Suzuka K, Seki K, Sekiya S: Subsequent pregnancy outcome in patients with spontaneous resolution of HCG after evacuation of hydatidiform mole: comparison between complete and partial mole. Hum Reprod; 2001 Jun;16(6):1274-7
Genetic Alliance. consumer health - Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subsequent pregnancy outcome in patients with spontaneous resolution of HCG after evacuation of hydatidiform mole: comparison between complete and partial mole.
  • This study compared subsequent pregnancy outcome in patients with complete and partial hydatidiform moles.
  • Among 1052 patients with molar pregnancy (complete mole, 801; partial mole, 251) monitored at Chiba University Hospital between 1981 and 1999, 891 patients (84.7%) had spontaneous resolution of human chorionic gonadotrophin (HCG) after mole evacuation, and 161 patients (15.3%) required chemotherapy.
  • The pregnancy outcome was not significantly different in patients with complete and partial moles, and was comparable with that in the general Japanese population.
  • The incidence of repeat molar pregnancy in patients with complete and partial mole (1.3 and 1.5% respectively) was 5-fold higher than that of the general population, while no increased risk of persistent gestational trophoblastic tumour (GTT) associated with later molar pregnancy was observed.
  • During HCG follow-up, 10 patients (1.1%) developed secondary high-risk GTT between 14 and 54 months after mole evacuation.
  • In conclusion, patients with complete and partial mole can anticipate a normal future reproductive outcome, and pregnancies after experiencing hydatidiform mole may not affect the development of high-risk GTT.
  • [MeSH-major] Chorionic Gonadotropin / blood. Hydatidiform Mole / surgery. Pregnancy Outcome
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Middle Aged. Pregnancy. Recurrence. Risk Factors. Trophoblastic Neoplasms / epidemiology. Trophoblastic Neoplasms / etiology. Uterine Neoplasms / epidemiology. Uterine Neoplasms / etiology

  • Genetic Alliance. consumer health - Hydatidiform mole.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11387305.001).
  • [ISSN] 0268-1161
  • [Journal-full-title] Human reproduction (Oxford, England)
  • [ISO-abbreviation] Hum. Reprod.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin
  •  go-up   go-down


56. Riadh BT, Abdellatif C, Wissal H, Leila A, Taher M, Abdelhamid K: Clinical analysis and management of gestational trophoblastic diseases: a 90 cases study. Int J Biomed Sci; 2009 Dec;5(4):321-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The aim of the study was to identify the incidence, diagnosis, therapeutic and histological particularities of molar pregnancies and to evaluate our management of gestational trophoblastic tumors (GTT) according to the recommendations of FIGO.
  • METHODS: This was a retrospective study of 90 patients who were diagnosed with molar pregnancy from January 1991 to December 2007.
  • After remission, post molar pregnancy surveillance was continued for one year.
  • Patients whose condition required chemotherapy for GTT were attributed a FIGO/WHO score.
  • RESULTS: Molar pregnancy occurred in 90 women.
  • The frequency of molar pregnancy was 1 per 1124 pregnancies.
  • Molar pregnancies were more frequent in pauciparous patients (52.24%).
  • Treatment consisted in uterine evacuation by suction curettage.
  • Histological findings were complete mole in 66.66% of the cases and partial mole in 33.33% of the cases.
  • 81 patients (90%) achieved remission without chemotherapy and 9 patients (10%) had FIGO stage I GTT.
  • CONCLUSION: The practice of ultrasonography in the first trimester of pregnancy allows an early diagnosis of molar pregnancy and an adequate treatment and follow-up.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23675154.001).
  • [ISSN] 1550-9702
  • [Journal-full-title] International journal of biomedical science : IJBS
  • [ISO-abbreviation] Int J Biomed Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3614797
  • [Keywords] NOTNLM ; chemotherapy / gestational trophoblastic tumors / human chorionic gonadotropin / hydatiform mole / ultrasonography
  •  go-up   go-down


57. Growdon WB, Wolfberg AJ, Goldstein DP, Feltmate CM, Chinchilla ME, Lieberman ES, Berkowitz RS: Evaluating methotrexate treatment in patients with low-risk postmolar gestational trophoblastic neoplasia. Gynecol Oncol; 2009 Feb;112(2):353-7
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluating methotrexate treatment in patients with low-risk postmolar gestational trophoblastic neoplasia.
  • METHODS: We studied 150 women with persistent GTN after diagnosis of complete (n=110) or partial mole (n=40) to identify possible predictors of requiring additional treatment after a single treatment of methotrexate (MTX).
  • RESULTS: Seventy women (47%) required additional courses of chemotherapy, of whom 45 (64%) received chemotherapy other than MTX.
  • Multivariate analysis revealed that complete mole histology, presence of metastasis, single day MTX infusion and any increase in serum beta human chorionic gonadotropin (beta-hCG) level 1 week after MTX therapy were independent predictors of requiring additional MTX or alternative chemotherapy.
  • Dilatation and curettage (D+C) within 1 week after the diagnosis of persistence did not affect future chemotherapy requirements (p>0.64).
  • Following complete mole, beta-hCG levels >2000 mIU/mL at 1 week post MTX were associated with a 89% risk of additional cycles chemotherapy including MTX and a 65% risk of alternative chemotherapy.
  • CONCLUSIONS: Metastatic disease, MTX infusion protocol and complete mole histology were independently associated with the need for additional chemotherapy after an initial course of MTX for women with low risk GTN.
  • D+C at persistence did not alter the chemotherapy requirement.
  • Elevated beta-hCG level at 1 week after the initial course of MTX was also an independent factor predicting the need for additional courses of MTX or alternative chemotherapy.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Gestational Trophoblastic Disease / drug therapy. Methotrexate / therapeutic use
  • [MeSH-minor] Adult. Chorionic Gonadotropin, beta Subunit, Human / blood. Female. Humans. Hydatidiform Mole / pathology. Neoplasm Staging. Predictive Value of Tests. Pregnancy. Risk Factors

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19059633.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Chorionic Gonadotropin, beta Subunit, Human; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


58. Zhou Q, Lei XY, Xie Q, Cardoza JD: Sonographic and Doppler imaging in the diagnosis and treatment of gestational trophoblastic disease: a 12-year experience. J Ultrasound Med; 2005 Jan;24(1):15-24
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sonographic and Doppler imaging in the diagnosis and treatment of gestational trophoblastic disease: a 12-year experience.
  • OBJECTIVE: To evaluate the clinical utility of sonography with Doppler examination in the diagnosis and treatment of gestational trophoblastic disease (GTD).
  • Sonographic and Doppler examinations were performed to diagnose the presence of molar tissue, detect invasive disease, assess disease recurrence, and monitor the efficacy of chemotherapy.
  • RESULTS: Of the 355 patients with GTD, 106 had a classic hydatidiform mole (CHM), 33 had a partial hydatidiform mole (PHM), 184 had an invasive hydatidiform mole (IHM), and 32 had choriocarcinoma.
  • Sonography showed abnormal molar tissue confined to the endometrial cavity in all cases of CHM.
  • In cases of IHM and choriocarcinoma, soft tissue invasion and cystic vascular spaces within the myometrium were shown.
  • Doppler waveforms showed resistive indices of 0.55 (SD, 0.06) for CHM, 0.56 (SD, 0.04) for PHM, 0.28 (SD, 0.06) for IHM, 0.25 (SD, 0.05) for choriocarcinoma, and 0.66 (SD, 0.04) for normal pregnancies.
  • The abnormal sonographic and Doppler findings in invasive disease resolved when chemotherapy was successful.
  • CONCLUSIONS: Sonography and Doppler imaging were helpful in diagnosing GTD, in determining whether invasive disease was present, in detecting recurrence of disease, and in following the effectiveness of chemotherapy.
  • [MeSH-minor] Adult. Choriocarcinoma / ultrasonography. Female. Humans. Hydatidiform Mole / ultrasonography. Middle Aged. Pregnancy. Ultrasonography, Doppler

  • Genetic Alliance. consumer health - Gestational Trophoblastic Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15615924.001).
  • [ISSN] 0278-4297
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Xu BP, Zhang YQ, Li SP: [Effect of relieving blood stasis, strengthening spleen and soothing liver therapy in improving hepatic function in patients after liver-carcinomectomy]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2001 Oct;21(10):742-3
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of relieving blood stasis, strengthening spleen and soothing liver therapy in improving hepatic function in patients after liver-carcinomectomy].
  • OBJECTIVE: To improve hepatic function with Chinese herbal medicine (CHM) in patients after liver-carcinomectomy.
  • METHODS: One hundred and twenty patients were divided into the CHM group (61 patients) and the control group (59 patients).
  • CHM therapy for relieving blood stasis, invigorating Spleen and soothing Liver was given to the CHM group after liver-carcinomectomy continuously for 5-6 weeks, and hepatic function was examined in all patients 8-9 weeks after the operation.
  • RESULTS: The hepatic function indexes, including alanine transaminase (ALT), aspartate aminotrasferase (AST), serum albumin (ALB), gamma glutamyl transpeptidase (GGTP), total bilirubin (TBIL) and direct bilirubin (DBIL), were improved in the CHM group more significantly than those in the control group, all P < 0.05.
  • CONCLUSION: Relieving blood stasis, strengthening Spleen and soothing Liver therapy has good effect in improving hepatic function after liver-carcinomectomy.

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12575605.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


60. May BH, Yang AW, Zhang AL, Owens MD, Bennett L, Head R, Cobiac L, Li CG, Hugel H, Story DF, Xue CC: Chinese herbal medicine for Mild Cognitive Impairment and Age Associated Memory Impairment: a review of randomised controlled trials. Biogerontology; 2009 Apr;10(2):109-23
PubMed Health. DARE review .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This review assesses the effectiveness and safety of Chinese herbal medicines (CHM) for Mild Cognitive Impairment (MCI) and Age Associated Memory Impairment (AAMI).
  • Randomised controlled trials comparing orally administered CHM with placebo, no intervention or other therapy were considered.
  • Eight different CHM were investigated.
  • Two studies compared CHM with placebo and eight with another intervention.
  • This review found an overall benefit on some outcome measures for the eight CHMs involved in the 10 RCTs but methodological and data reporting issues were evident.
  • Meta-analysis of three studies found the effects of the CHMs were at least equivalent to piracetam on Mini-Mental State Examination (MMSE) scores.
  • [MeSH-major] Aging. Cognition / drug effects. Cognition Disorders / drug therapy. Drugs, Chinese Herbal / therapeutic use. Memory / drug effects. Memory Disorders / drug therapy. Nootropic Agents / therapeutic use
  • [MeSH-minor] Administration, Oral. Aged. Aged, 80 and over. Female. Humans. Male. Mental Status Schedule. Middle Aged. Randomized Controlled Trials as Topic. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Memory.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18716893.001).
  • [ISSN] 1389-5729
  • [Journal-full-title] Biogerontology
  • [ISO-abbreviation] Biogerontology
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 0 / Nootropic Agents
  • [Number-of-references] 45
  •  go-up   go-down


61. Cui Y, Shu XO, Gao Y, Wen W, Ruan ZX, Jin F, Zheng W: Use of complementary and alternative medicine by chinese women with breast cancer. Breast Cancer Res Treat; 2004 Jun;85(3):263-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study is to evaluate the prevalence and patterns of CAM use, particularly patients' intentions and their perceived effectiveness of using Chinese herbal medicine (CHM), as well as the relations between the herbal medicine use and demographic and clinical factors among Chinese women with breast cancer.
  • Patients' average age at diagnosis was 48.1 years and the median time from the initial diagnosis to the follow-up survey was 4.3 years.
  • Overall, 98% of patients had used at least one form of CAM therapy after diagnosis of breast cancer.
  • CHM was used by 86.4% of patients, while acupuncture was used only by 4.9% of patients.
  • Treating cancer (81.5%) was the most common intentions of using CHM.
  • The majority of patients reported that they had benefited from the use of CHM.
  • Patients who were younger, married, had higher education or income, received chemotherapy or radiotherapy, or had recurrence/metastasis of cancer tended to use CHM more frequently than other patients.
  • The relations between patient characteristics and use of CHMs varied with users' intentions.
  • [MeSH-major] Attitude to Health. Breast Neoplasms / therapy. Complementary Therapies / utilization. Drugs, Chinese Herbal / therapeutic use. Phytotherapy / utilization

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Complementary and Integrative Medicine.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Kluwer Academic Publishers
  • [ErratumIn] Breast Cancer Res Treat. 2004 Jul;86(1):89
  • (PMID = 15111765.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01CA64277
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal
  •  go-up   go-down


62. Ji YI, Jung MH: Gastrointestinal bleeding caused by ileal metastasis of a tubal complete mole: a case report. J Womens Health (Larchmt); 2010 Jun;19(6):1217-20
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal bleeding caused by ileal metastasis of a tubal complete mole: a case report.
  • BACKGROUND: Tubal hydatidiform mole is known to be an extremely rare disease, moreover, gastrointestinal metastasis from an ectopic complete mole has never been reported.
  • She had undergone laparoscopic left salpingectomy for a tubal complete mole a month earlier.
  • An ileal invasion of mole was identified.
  • The patient received nine cycles of adjuvant methotrexate chemotherapy after small bowel resection and anastomosis.
  • She was been without recurrence 20 months after therapy.
  • DISCUSSION: Gestational trophoblastic diseases in ectopic pregnancy are rare and gastrointestinal tract metastasis is very infrequent.
  • To our knowledge, this is the first report of molar pregnancy in a Fallopian tube with ileal metastasis.
  • CONCLUSION: Ectopic molar pregnancy with gastrointestinal metastasis carries a high risk of intestinal perforation and uncontrollable gastrointestinal bleeding.
  • Despite its rarity, gastrointestinal metastasis should nevertheless be considered a possible cause for gastrointestinal bleeding in ectopic molar pregnancy patients after elimination of the more common etiologies.
  • [MeSH-major] Gastrointestinal Hemorrhage / etiology. Hydatidiform Mole / secondary. Ileal Neoplasms / secondary. Pregnancy, Tubal
  • [MeSH-minor] Adult. Female. Humans. Ileum / pathology. Pregnancy

  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20392142.001).
  • [ISSN] 1931-843X
  • [Journal-full-title] Journal of women's health (2002)
  • [ISO-abbreviation] J Womens Health (Larchmt)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Ni LJ, Zhang LG, Hou J, Shi WZ, Guo ML: A strategy for evaluating antipyretic efficacy of Chinese herbal medicines based on UV spectra fingerprints. J Ethnopharmacol; 2009 Jul 6;124(1):79-86
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ETHNOPHARMACOLOGICAL RELEVANCE: Quality analysis and control of Chinese herbal medicines (CHM) or herbal medicines (HM) are being more and more investigated based on fingerprint analysis, and there are also some researches on correlating fingerprints of CHM to their efficacy.
  • Multi-component analysis methods together with fingerprints are considered potential useful tools to select candidate herbal drugs from extracts of herbs in pharmacological/bio-prospecting investigations.
  • AIM OF THE STUDY: To explore a strategy for evaluating efficacy strength of CHM samples based on their spectra fingerprints and validate it.
  • Principal component analysis (PCA) and canonical correlation analysis (CCA) were adopted as evaluation tools to establish the correlation between pharmacological and spectra data, from which a spectral index for evaluating antipyretic effects of CHM samples was constructed.
  • RESULTS: Efficacy sequence of the 15 calibrating and 4 validating CHM samples, defined by the first canonical correlative variable U(1) of their UV spectra, was consistent with that given by pharmacological experiments.
  • CONCLUSIONS: The strategy proposed in this study could be applied to evaluate efficacy strength of CHM and helpful for screening candidate herbal drugs from different herbs or prepared by different technologies.
  • [MeSH-major] Angiosperms. Drugs, Chinese Herbal / therapeutic use. Fever / drug therapy. Phytotherapy. Spectrophotometry, Ultraviolet / methods
  • [MeSH-minor] Animals. Bupleurum. Evaluation Studies as Topic. Female. Flowers. Forsythia. Fruit. Herbal Medicine / methods. Ibuprofen / pharmacology. Ibuprofen / therapeutic use. Lonicera. Male. Medicine, Chinese Traditional. Oils, Volatile / pharmacology. Oils, Volatile / therapeutic use. Plant Roots. Principal Component Analysis / methods. Rats. Rats, Sprague-Dawley. Reproducibility of Results

  • MedlinePlus Health Information. consumer health - Fever.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • Hazardous Substances Data Bank. IBUPROFEN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19527822.001).
  • [ISSN] 1872-7573
  • [Journal-full-title] Journal of ethnopharmacology
  • [ISO-abbreviation] J Ethnopharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 0 / Oils, Volatile; WK2XYI10QM / Ibuprofen
  •  go-up   go-down


64. Zhu X, Proctor M, Bensoussan A, Smith CA, Wu E: Chinese herbal medicine for primary dysmenorrhoea. Cochrane Database Syst Rev; 2007;(4):CD005288
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Conventional treatment for primary dysmenorrhoea (PD) has a failure rate of 20% to 25% and may be contraindicated or not tolerated by some women.
  • Chinese herbal medicine (CHM) may be a suitable alternative.
  • OBJECTIVES: To determine the efficacy and safety of CHM for PD when compared with placebo, no treatment, and other treatment.
  • SELECTION CRITERIA: Any randomised controlled trials (RCTs) involving CHM versus placebo, no treatment, conventional therapy, heat compression, another type of CHM, acupuncture or massage.
  • Results for CHM compared to placebo were unclear as data could not be combined (3 RCTs).
  • CHM resulted in significant improvements in pain relief (14 RCTs; RR 1.99, 95% CI 1.52 to 2.60), overall symptoms (6 RCTs; RR 2.17, 95% CI 1.73 to 2.73) and use of additional medication (2 RCTs; RR 1.58, 95% CI 1.30 to 1.93) when compared to use of pharmaceutical drugs.
  • Self-designed CHM resulted in significant improvements in pain relief (18 RCTs; RR 2.06, 95% CI 1.80 to 2.36), overall symptoms (14 RCTs; RR 1.99, 95% CI 1.65 to 2.40) and use of additional medication (5 RCTs; RR 1.58, 95% CI 1.34 to 1.87) after up to three months follow up when compared to commonly used Chinese herbal health products.
  • CHM also resulted in better pain relief than acupuncture (2 RCTs; RR 1.75, 95% CI 1.09 to 2.82) and heat compression (1 RCT; RR 2.08, 95% CI 2.06 to 499.18).
  • AUTHORS' CONCLUSIONS: The review found promising evidence supporting the use of CHM for primary dysmenorrhoea; however, results are limited by the poor methodological quality of the included trials.
  • [MeSH-major] Drugs, Chinese Herbal / therapeutic use. Dysmenorrhea / drug therapy. Phytotherapy / methods

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • MedlinePlus Health Information. consumer health - Period Pain.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateIn] Cochrane Database Syst Rev. 2008;(2):CD005288 [18425916.001]
  • (PMID = 17943847.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal
  • [Number-of-references] 99
  •  go-up   go-down


65. Huh WK, Powell M, Leath CA 3rd, Straughn JM Jr, Cohn DE, Gold MA, Falkner CA, Carey DE, Herzog T, Fowler JM, Partridge EE, Kilgore LC, Alvarez RD: Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy. Gynecol Oncol; 2003 Dec;91(3):470-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy.
  • OBJECTIVE: Our aim was to determine the outcomes of Stage I uterine papillary serous carcinoma (UPSC) patients with and without adjuvant therapy after comprehensive surgical staging.
  • RESULTS: Of the 60 Stage I patients, 40 (66%) patients received no adjuvant therapy, 12 (20%) received adjuvant radiation therapy (XRT), 7 (12%) received adjuvant chemotherapy (CHM), and 1 (2%) received both XRT and CHM.
  • No recurrences or deaths were observed in the CHM group.
  • The risk of recurrence and the mean overall survival were similar between surgical Stage I UPSC patients who were managed conservatively and those treated with adjuvant radiation therapy.
  • These data question the benefit of radiation therapy in UPSC patients with disease confined to the uterus.
  • Finally, given the absence of recurrences and disease-related deaths for adjuvant chemotherapy in these patients, a Phase II/III trial evaluating adjuvant chemotherapy in surgical Stage I UPSC patients should be considered.
  • [MeSH-major] Cystadenocarcinoma, Papillary / therapy. Uterine Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Cohort Studies. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gynecol Oncol. 2003 Dec;91(3):461-2 [14675662.001]
  • (PMID = 14675664.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Xue CC, Thien FC, Zhang JJ, Da Costa C, Li CG: Treatment for seasonal allergic rhinitis by Chinese herbal medicine: a randomized placebo controlled trial. Altern Ther Health Med; 2003 Sep-Oct;9(5):80-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment for seasonal allergic rhinitis by Chinese herbal medicine: a randomized placebo controlled trial.
  • CONTEXT: Chinese herbal medicine (CHM) is widely used to treat seasonal allergic rhinitis (SAR), however, evidence of efficacy is lacking.
  • OBJECTIVE: To evaluate the efficacy of a Chinese herbal formulation for the treatment of SAR.
  • INTERVENTIONS: CHM extract capsule (containing 18 herbs) or placebo, given daily for 8 weeks.
  • After eight weeks, the severity of nasal symptoms and non-nasal symptoms were significantly less in the active treatment group than in the control group, both for measurements made by patients and those by the practitioner.
  • Comparison of active and placebo treatment groups RQLQ scores also indicated significant beneficial effects of treatment (end point Section 1: P < 0.05; Section 2: P < 0.01).
  • CONCLUSIONS: This CHM formulation appears to offer symptomatic relief and improvement of quality of life for some patients with seasonal allergic rhinitis.
  • [MeSH-major] Anti-Allergic Agents / therapeutic use. Drugs, Chinese Herbal / therapeutic use. Phytotherapy. Rhinitis, Allergic, Seasonal / drug therapy
  • [MeSH-minor] Adult. Aged. Australia. Dose-Response Relationship, Drug. Double-Blind Method. Female. Humans. Male. Middle Aged. Quality of Life. Severity of Illness Index. Surveys and Questionnaires. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Allergic rhinitis.
  • MedlinePlus Health Information. consumer health - Hay Fever.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14526714.001).
  • [ISSN] 1078-6791
  • [Journal-full-title] Alternative therapies in health and medicine
  • [ISO-abbreviation] Altern Ther Health Med
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Allergic Agents; 0 / Drugs, Chinese Herbal
  •  go-up   go-down


67. Ding SP, Li JC, Xu J, Mao LG: Study on the mechanism of regulation on the peritoneal lymphatic stomata with Chinese herbal medicine. World J Gastroenterol; 2002 Feb;8(1):188-92
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To study the mechanism of Chinese herbal medicine (CHM), the prescription consists of Radix Salviae Miltiorrhizae, Radix Codonopsitis Pilosulae, Rhizoma Atractylodis Alba and Rhizoma Alismatis, Leonurus Heterophyllus Sweet,etc on the regulation of the peritoneal lymphatic stomata and the ascites drainage.
  • RESULTS: Two different doses of CHM could significantly increase the area of the peritoneal lymphatic stomata, promote its distributive density and enhance the drainage of urinary ion such as sodium, potassium and chlorine.
  • Meanwhile, the NO concentration of two different doses of CHM groups was 133.52+/-23.57 micromol/L and 137.2+/-26.79 micromol/L respectively.
  • The effect of Chinese herbal medicine on the peritoneal lymphatic stomata and the drainage of urinary ion was altered by adding NO donor(sodium nitropurruside,SNP) or NO synthase (NOS) inhibitor (N(G)-monomethyl-L-arginine, L-NMMA) to the peritoneal cavity.
  • [MeSH-major] Ascites / drug therapy. Drugs, Chinese Herbal / pharmacology. Lymphatic System / cytology. Peritoneum / cytology
  • [MeSH-minor] Animals. Chlorides / urine. Epithelium / metabolism. Epithelium / ultrastructure. Liver Cirrhosis / drug therapy. Liver Cirrhosis / metabolism. Liver Cirrhosis / pathology. Male. Mice. Microscopy, Electron, Scanning. Nitric Oxide / blood. Potassium / urine. Sodium / urine

  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. POTASSIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. SODIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11833101.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Chlorides; 0 / Drugs, Chinese Herbal; 31C4KY9ESH / Nitric Oxide; 9NEZ333N27 / Sodium; RWP5GA015D / Potassium
  • [Other-IDs] NLM/ PMC4656617
  •  go-up   go-down


68. Zhang J, Li T, Zhou L, Tang L, Xu L, Wu T, Lim DC: Chinese herbal medicine for subfertile women with polycystic ovarian syndrome. Cochrane Database Syst Rev; 2010;(9):CD007535
Hazardous Substances Data Bank. CLOMIPHENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, many studies have been published considering Chinese herbal medicine (CHM) as an alternative treatment for women with PCOS.
  • SELECTION CRITERIA: Randomized controlled trials (RCT) considering the use of CHM for the treatment of subfertile women with PCOS.
  • Different interventions were used in these four RCTs.There was evidence of statistically significant difference seen improving pregnancy rate (per woman) between CHM plus clomiphene and clomiphene (OR 2.97, 95%CI 1.71 to 5.17).
  • However, there was no statistically significant difference seen in the other comparison groups for improving pregnancy rate (per woman).There was no evidence of statistically significant difference in improving ovulation rate (per woman) between CHM and clomiphene (OR 1.42, 95%CI 0.19 to 10.49), between CHM plus laparoscopic ovarian drilling (LOD) and LOD (OR 2.43, 95%CI 0.39 to 15.08).There were not statistically significant difference between CHM plus follicle aspiration, ovulation induction and follicle aspiration plus ovulation induction for adverse events including LUFS, OHSS and multiple pregnancy.Live birth rate was not reported by any studies.
  • AUTHORS' CONCLUSIONS: There is limited evidence that the addition of CHM to clomiphene is associated with improved clinical pregnancy outcomes and no other evidence of any other effect.
  • [MeSH-major] Drugs, Chinese Herbal / therapeutic use. Infertility / drug therapy. Polycystic Ovary Syndrome / complications
  • [MeSH-minor] Clomiphene / therapeutic use. Female. Fertility Agents, Female / therapeutic use. Humans. Pregnancy. Randomized Controlled Trials as Topic

  • Genetic Alliance. consumer health - Polycystic ovarian syndrome.
  • MedlinePlus Health Information. consumer health - Infertility.
  • MedlinePlus Health Information. consumer health - Polycystic Ovary Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20824862.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 0 / Fertility Agents, Female; 1HRS458QU2 / Clomiphene
  • [Number-of-references] 177
  •  go-up   go-down


69. Gauchez AS, Dreux S, Stéfani L, Mousseau M, Jouk PS, Muller F: Could ovarian choriocarcinoma be detected by maternal serum screening for Down syndrome? Prenat Diagn; 2007 Jul;27(7):682-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ovarian malignancies that produce human chorionic gonadotropin (hCG) are limited to germ cell tumors, of which dysgerminoma is the most frequent (45%) malignant type encountered in pregnant patients, the others being ovarian choriocarcinoma and mixed germ cell tumors (Boulay and Podczaski, 1998).
  • In women of childbearing age, it is hard to distinguish between metastatic choriocarcinoma on a complete mole and primary ovarian choriocarcinoma.
  • Treatment is based on adnexectomy followed by chemotherapy.
  • Had the diagnosis for our patient been made during pregnancy, the therapeutic approach would have been discussed in terms of gestational age.
  • In the last trimester, we could have suggested cesarean section followed by adnexectomy, and then chemotherapy.
  • In the second-trimester, chemotherapy could have been discussed, although the fetal toxicity of cisplatin chemotherapy is not firmly defined (Ferrandina et al., 2005).
  • This treatment is an alternative to termination of pregnancy.
  • We retrospectively studied maternal serum biochemistry so as to assess the possibility of a diagnosis of ovarian choriocarcinoma at the time of maternal serum screening for Down syndrome.
  • [MeSH-minor] Adult. Female. Humans. Infant, Newborn. Infant, Premature. Mass Screening. Pregnancy

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • Genetic Alliance. consumer health - Down Syndrome.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17533625.001).
  • [ISSN] 0197-3851
  • [Journal-full-title] Prenatal diagnosis
  • [ISO-abbreviation] Prenat. Diagn.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chorionic Gonadotropin, beta Subunit, Human
  •  go-up   go-down


70. Chen LM, Lengyel ER, Bethan Powell C: Single-agent pulse dactinomycin has only modest activity for methotrexate-resistant gestational trophoblastic neoplasia. Gynecol Oncol; 2004 Jul;94(1):204-7
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Patients had antecedent pregnancies of complete mole (7), partial mole (1), missed abortion (1), and choriocarcinoma (1).
  • One patient underwent hysterectomy during methotrexate treatment.
  • Six of 10 (60%) patients achieved complete remission with single-agent pulse dactinomycin.
  • In 33 cycles of chemotherapy administered, there were 46 toxicity events: all events were graded as 1.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Dactinomycin / therapeutic use. Gestational Trophoblastic Disease / drug therapy. Methotrexate / pharmacology
  • [MeSH-minor] Adult. Drug Administration Schedule. Drug Resistance, Neoplasm. Female. Humans. Middle Aged. Pregnancy. Risk Factors

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15262143.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 1CC1JFE158 / Dactinomycin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


71. Tasci Y, Dilbaz S, Secilmis O, Dilbaz B, Ozfuttu A, Haberal A: Routine histopathologic analysis of product of conception following first-trimester spontaneous miscarriages. J Obstet Gynaecol Res; 2005 Dec;31(6):579-82
MedlinePlus Health Information. consumer health - Miscarriage.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To evaluate the histopathologic findings relating to tissue samples collected at surgical uterine evacuation in first-trimester spontaneous miscarriages.
  • METHODS: In this retrospective study, histopathologic diagnosis of the tissue samples obtained via surgical uterine evacuation in patients who were admitted to the Early Pregnancy Clinic in a 12-month period with the diagnosis of incomplete miscarriage (n = 970), missed miscarriage (n = 406) and anembryonic miscarriage (n = 230) in the first trimester was recorded and compared with the presurgery diagnosis.
  • Histopathologic examination revealed the product of conception in 1119 patients (69.7%), while partial hydatidiform mole was diagnosed in 33 patients (2.1%).
  • Complete hydatidiform mole was detected in only seven cases (0.43%).
  • Decidual tissue without chorionic villi was reported in 272 patients (16.9%), raising the suspicion of presence of other pathology.
  • CONCLUSIONS: By routine histopathologic assessment of products of first-trimester spontaneous miscarriages, important pathologies such as molar pregnancy and placental trophoblastic disease can be diagnosed.
  • Histopathological assessment has great value in the identification of an ectopic pregnancy or infection when compared with clinical and laboratory findings.
  • [MeSH-minor] Abortion, Incomplete / pathology. Abortion, Missed / pathology. Adolescent. Adult. Decidua / pathology. Female. Gestational Trophoblastic Disease / pathology. Humans. Hydatidiform Mole / pathology. Middle Aged. Pregnancy. Pregnancy Trimester, First. Retrospective Studies. Uterine Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343264.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


72. van Trommel NE, Sweep FC, Schijf CP, Massuger LF, Thomas CM: Diagnosis of hydatidiform mole and persistent trophoblastic disease: diagnostic accuracy of total human chorionic gonadotropin (hCG), free hCG {alpha}- and {beta}-subunits, and their ratios. Eur J Endocrinol; 2005 Oct;153(4):565-75
Genetic Alliance. consumer health - Hydatidiform mole.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of hydatidiform mole and persistent trophoblastic disease: diagnostic accuracy of total human chorionic gonadotropin (hCG), free hCG {alpha}- and {beta}-subunits, and their ratios.
  • OBJECTIVE: Human chorionic gonadotropin (hCG) is widely used in the management of hydatidiform mole and persistent trophoblastic disease (PTD).
  • Predicting PTD after molar pregnancy might be beneficial since prophylactic chemotherapy reduces the incidence of PTD.
  • DESIGN: A retrospective study based on blood specimens collected in the Dutch Registry for Hydatidiform Moles.
  • A group of 165 patients with complete moles (of which 43 had PTD) and 39 patients with partial moles (of which 7 had PTD) were compared with 27 pregnant women with uneventful pregnancy.
  • METHODS: Serum samples from patients with hydatidiform mole with or without PTD were assayed using specific (radio) immunoassays for free alpha-subunit (hCGalpha), free beta-subunit (hCGbeta) and 'total' hCG (hCG + hCGbeta).
  • RESULTS: hCGbeta, hCGbeta/hCG + hCGbeta and hCGalpha/hCGbeta show AUCs ranging between 0.922 and 0.999 and, therefore, are excellent diagnostic tests to distinguish complete and partial moles from normal pregnancy.
  • To distinguish partial from complete moles the analytes hCGbeta, hCG + hCGbeta and the ratio hCGalpha/hCGbeta have AUCs between 0.7 and 0.8.
  • Although hCGalpha, hCGbeta and hCG + hCGbeta concentrations are significantly elevated in patients who will develop PTD compared with patients with spontaneous regression after evacuation of their moles, in predicting PTD, these analytes and parameters have AUCs <0.7.
  • CONCLUSIONS: Distinction between hydatidiform mole and normal pregnancy is best shown by a single blood specimen with hCGbeta, but hCGbeta/hCG + hCGbeta and hCGalpha/hCGbeta are also excellent diagnostic parameters.
  • To predict PTD, hCGalpha, hCGbeta, hCG + hCGbeta and hCGalpha/hCGbeta are moderately accurate tests, although they are not accurate enough to justify prophylactic chemotherapy treatment for prevention of PTD.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16189178.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin; 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / Glycoprotein Hormones, alpha Subunit
  •  go-up   go-down


73. Sebire NJ, Foskett M, Fisher RA, Lindsay I, Seckl MJ: Persistent gestational trophoblastic disease is rarely, if ever, derived from non-molar first-trimester miscarriage. Med Hypotheses; 2005;64(4):689-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistent gestational trophoblastic disease is rarely, if ever, derived from non-molar first-trimester miscarriage.
  • Traditional epidemiologic data suggest that persistent gestational trophoblastic disease (pGTD), may follow, and be derived from, either molar pregnancy, non-molar term pregnancy or first-trimester non-molar miscarriage.
  • We examined a database of cases of possible or probable hydatidiform moles and proven pGTD derived from the Regional Trophoblastic Disease Unit, Charing Cross Hospital, London.
  • There were 424 cases (6%), in whom the initial registered diagnosis was that of PHM or CHM but central histopathological review diagnosed a definite non-molar hydropic abortion (HA).
  • In eight of the 424 (2%), although the histology of the most recent index pregnancy was that of non-molar miscarriage, there was a previous history of pregnancy affected by hydatidiform mole; two of these developed subsequent pGTD.
  • Of a further 86 cases referred for a histopathological opinion prior to registration which demonstrated definite non-molar HA, none developed pGTD (zero of 510 (0%, 95% CI 0-0.7%)).
  • During the same period there were 352 cases with pGTD requiring chemotherapy.
  • In 31 cases, the only known pregnancy was the preceding apparent non-molar HA.
  • However, of these, there were only three cases in whom the preceding histological products of conception had been centrally reviewed and were suggestive of non-molar pregnancy.
  • However, in all three of these cases, the specimens were inadequate for definite exclusion of molar pregnancy.
  • In one case in whom no material was available for review, molecular genetic analysis using restriction fragment length polymorphisms was carried out, and the choriocarcinoma was genetically derived from a previous molar pregnancy rather than the preceding HA.
  • There were therefore no cases identified on the database of the trophoblastic disease unit of pGTD requiring treatment in whom the trophoblastic tumour could be genetically proven to have arisen from the preceding first trimester non-molar HA.
  • We suggest that the risk of pGTD developing from a histologically confirmed non-molar HA is less than 1 in 50,000 and that the majority of pGTD cases previously reported to have been caused by a non-molar miscarriage probably represent disease due to an unrecognised early molar pregnancy.
  • [MeSH-major] Abortion, Spontaneous. Gestational Trophoblastic Disease / etiology. Pregnancy Trimester, First
  • [MeSH-minor] Female. Humans. Pregnancy

  • Genetic Alliance. consumer health - Gestational Trophoblastic Disease.
  • MedlinePlus Health Information. consumer health - Miscarriage.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15694683.001).
  • [ISSN] 0306-9877
  • [Journal-full-title] Medical hypotheses
  • [ISO-abbreviation] Med. Hypotheses
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


74. Chen M, Zheng H, Yin LP, Xie CG: Is oral administration of Chinese herbal medicine effective and safe as an adjunctive therapy for managing diabetic foot ulcers? A systematic review and meta-analysis. J Altern Complement Med; 2010 Aug;16(8):889-98
MedlinePlus Health Information. consumer health - Herbal Medicine.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is oral administration of Chinese herbal medicine effective and safe as an adjunctive therapy for managing diabetic foot ulcers? A systematic review and meta-analysis.
  • OBJECTIVE: This meta-analysis aimed to assess the effectiveness and safety of Chinese herbal medicine (CHM) as an adjunctive method to standard therapy for patients with diabetic foot ulcers (DFU).
  • METHODS: Randomized controlled trials (RCTs) of CHM to treat DFU were searched in the following electronic databases: MEDLINE; EMBASE; Chinese Biomedical Database (CBM); Cochrane Central Register of Controlled Trials (CENTRAL); Allied & Complementary Medicine Resources (AMED); and Cumulative Index to Nursing and Allied Health Literature (CINAHL).
  • Compared to using standard therapy alone, CHM combined with standard therapy significantly increased the number of patients whose ulcers healed (risk ratio [RR], 0.62, [95% confidence interval (CI), 0.39-0.97]) and number of patients with at least a 30% reduction in the ulcer area (RR, 0.81 [95%CI, 0.71-0.92]).
  • In addition, the two therapies combined significantly decreased the number of patients without any improvement (RR, 0.34 [95%CI, 0.21-0.53]).
  • However, with respect to blood flow volume in the dorsal artery of the foot, no significant difference between the two therapies was observed (standardized mean difference, 1.71 [95% CI -1.25-4.67]), but the result favored the CHM combined with standard therapy group.
  • CONCLUSIONS: CHM may be effective and safe as an adjunctive therapy for treating DFU.
  • [MeSH-major] Diabetic Foot / drug therapy. Drugs, Chinese Herbal / therapeutic use. Phytotherapy / methods. Plant Extracts / therapeutic use
  • [MeSH-minor] Adjuvants, Pharmaceutic. Administration, Oral. Humans. Randomized Controlled Trials as Topic. Treatment Outcome. Wound Healing / drug effects. Wound Infection / drug therapy

  • MedlinePlus Health Information. consumer health - Diabetic Foot.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20673140.001).
  • [ISSN] 1557-7708
  • [Journal-full-title] Journal of alternative and complementary medicine (New York, N.Y.)
  • [ISO-abbreviation] J Altern Complement Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Pharmaceutic; 0 / Drugs, Chinese Herbal; 0 / Plant Extracts
  •  go-up   go-down


75. Chen FP, Kung YY, Chen YC, Jong MS, Chen TJ, Chen FJ, Hwang SJ: Frequency and pattern of Chinese herbal medicine prescriptions for chronic hepatitis in Taiwan. J Ethnopharmacol; 2008 Apr 17;117(1):84-91
Genetic Alliance. consumer health - Hepatitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ETHNOPHARMACOLOGICAL RELEVANCE: Chinese herbal medicine (CHM) has been commonly used in treating liver diseases in Asian countries.
  • AIM OF STUDY: To conduct a large-scale pharmacoepidemiological study and evaluate the frequency and pattern of CHM prescriptions in treating chronic hepatitis.
  • Corresponding prescription files were analyzed, and association rule were applied to evaluate the co-prescription of CHM in treating chronic hepatitis.
  • RESULTS: Among the 91,080 subjects treated by CHM for chronic hepatitis, the peak age was in the 40 s, followed by 30 s and 50 s.
  • Long-dan-xie-gan-tang and Saliva miltiorrhiza (Dan-shen) were the most commonly prescribed Chinese herbal formula and single herbal drug, respectively.
  • The most common two-drug prescription was Jia-wei-xia-yao-san plus Saliva miltiorrhiza, and the most common three-drug prescription was Jia-wei-xia-yao-san plus Saliva miltiorrhiza and Artemisia capillaries (Yin-chen-hao).
  • CONCLUSIONS: This study showed the utilization pattern of Chinese herbal drugs or formulae in treating chronic hepatitis.
  • [MeSH-major] Drugs, Chinese Herbal / therapeutic use. Hepatitis, Chronic / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Drug Utilization. Glutathione / analysis. Humans. Infant. Infant, Newborn. L-Lactate Dehydrogenase / blood. Medicine, Chinese Traditional. Middle Aged. Taiwan

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18321671.001).
  • [ISSN] 0378-8741
  • [Journal-full-title] Journal of ethnopharmacology
  • [ISO-abbreviation] J Ethnopharmacol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; EC 1.1.1.27 / L-Lactate Dehydrogenase; GAN16C9B8O / Glutathione
  •  go-up   go-down


76. Du XH, Song WM, Xu AE: [Clinical effect of treatment for clearing heat, detoxicating and nourishing Yin on patients with glucocorticosteroid induced facial dermatitis and its effect on skin barrier function]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2006 Jan;26(1):46-8
MedlinePlus Health Information. consumer health - Steroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical effect of treatment for clearing heat, detoxicating and nourishing Yin on patients with glucocorticosteroid induced facial dermatitis and its effect on skin barrier function].
  • OBJECTIVE: To observe the clinical efficacy of treatment for clearing heat, detoxicating and nourishing Yin (abbr. as CHM) on glucocorticosteroid (GCS) induced facial dermatitis, and its effect in repairing skin barrier function.
  • METHODS: One hundred and fifteen patients were randomly assigned into two groups, 68 in the treated group treated with CHM and 47 in the control group treated by oral administration of loratadine 10 mg once a day and ketotifen 1 mg once every night.
  • The volume of transepidermal water loss (TEWL) of patients was measured before and after treatment.
  • CONCLUSION: Chinese herbal treatment for clearing heat, detoxicating and nourishing Yin has significant clinical efficiency on GCS induced facial dermatitis and in repairing the skin barrier function.

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16466172.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 0 / Glucocorticoids
  •  go-up   go-down


77. Sebire NJ, Seckl MJ: Immunohistochemical staining for diagnosis and prognostic assessment of hydatidiform moles: current evidence and future directions. J Reprod Med; 2010 May-Jun;55(5-6):236-46
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical staining for diagnosis and prognostic assessment of hydatidiform moles: current evidence and future directions.
  • OBJECTIVE: To review the published data on studies examining immunohistochemical markers of hydatidiform moles for determination of diagnosis or prognosis, with regard to whether such investigations can provide clinically relevant information.
  • STUDY DESIGN: Search of computerized literature databases to identify studies reporting on immunohistochemical findings in cases of hydatidiform mole followed by summarization and interpretation of the findings.
  • Some markers, such as P57(KIP2), show distinct differences in expression between groups and are useful in clinical practice for the diagnosis of complete hydatidiform moles.
  • Some markers appear to be associated with increased risk of progression to requiring chemotherapy, including increased expression of P53, EGFR, HER2, c-erbB-2 and telomerase and reduced expression of nm23.
  • CONCLUSION: Despite technical issues complicating overall interpretation, such as small sample size and the uncertainty of classification of hydatidiform moles in many studies, convincing data is reported for several markers, which should guide future studies.
  • [MeSH-major] Biomarkers, Tumor / analysis. Hydatidiform Mole / diagnosis. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Pregnancy. Prognosis


78. Ruan WJ, Lai MD, Zhou JG: Anticancer effects of Chinese herbal medicine, science or myth? J Zhejiang Univ Sci B; 2006 Dec;7(12):1006-14
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Currently there is considerable interest among oncologists to find anticancer drugs in Chinese herbal medicine (CHM).
  • In the past, clinical data showed that some herbs possessed anticancer properties, but western scientists have doubted the scientific validity of CHM due to the lack of scientific evidence from their perspective.
  • Recently there have been encouraging results, from a western perspective, in the cancer research field regarding the anticancer effects of CHM.
  • Experiments showed that CHM played its anticancer role by inducing apoptosis and differentiation, enhancing the immune system, inhibiting angiogenesis, reversing multidrug resistance (MDR), etc.
  • Clinical trials demonstrated that CHM could improve survival, increase tumor response, improve quality of life, or reduce chemotherapy toxicity, although much remained to be determined regarding the objective effects of CHM in human in the context of clinical trials.
  • Interestingly, both laboratory experiments and clinical trials have demonstrated that when combined with chemotherapy, CHM could raise the efficacy level and lower toxic reactions.
  • These facts raised the feasibility of the combination of herbal medicines and chemotherapy, although much remained to be investigated in this area.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Drugs, Chinese Herbal / pharmacology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Trials as Topic. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ai Zheng. 2004 Dec;23(12):1599-604 [15601545.001]
  • [Cites] Anticancer Res. 2004 Mar-Apr;24(2C):1293-302 [15154663.001]
  • [Cites] Blood. 1996 Aug 1;88(3):1052-61 [8704214.001]
  • [Cites] Clin Chim Acta. 2004 Oct;348(1-2):41-8 [15369734.001]
  • [Cites] J Clin Oncol. 2004 Sep 15;22(18):3705-12 [15289492.001]
  • [Cites] Ther Drug Monit. 2005 Feb;27(1):53-7 [15665747.001]
  • [Cites] Biochem Pharmacol. 1999 Dec 1;58(11):1685-93 [10571242.001]
  • [Cites] Eur J Cancer. 1999 Oct;35(10):1541-5 [10673984.001]
  • [Cites] Cancer Lett. 2000 Aug 31;157(1):65-75 [10893444.001]
  • [Cites] J Gastroenterol. 2001 Feb;36(2):79-90 [11227675.001]
  • [Cites] Nihon Rinsho Meneki Gakkai Kaishi. 2001 Feb;24(1):10-20 [11280896.001]
  • [Cites] Int Immunopharmacol. 2001 Oct;1(11):1947-56 [11606026.001]
  • [Cites] Planta Med. 2001 Nov;67(8):754-7 [11731922.001]
  • [Cites] J Cell Biochem. 2002;84(3):532-44 [11813258.001]
  • [Cites] Int J Oncol. 2002 Apr;20(4):681-9 [11894110.001]
  • [Cites] Phytother Res. 2002 Mar;16(2):117-21 [11933111.001]
  • [Cites] Planta Med. 2002 Apr;68(4):370-2 [11988868.001]
  • [Cites] Int J Cancer. 2002 May 10;99(2):286-91 [11979446.001]
  • [Cites] Blood Cells Mol Dis. 2002 Mar-Apr;28(2):160-8 [12064912.001]
  • [Cites] Planta Med. 2002 Jun;68(6):550-3 [12094304.001]
  • [Cites] N Engl J Med. 1998 Nov 5;339(19):1341-8 [9801394.001]
  • [Cites] Chin Med J (Engl). 2003 Jan;116(1):148-50 [12667410.001]
  • [Cites] World J Gastroenterol. 2003 Apr;9(4):670-3 [12679907.001]
  • [Cites] Science. 2003 May 2;300(5620):740-1 [12730581.001]
  • [Cites] Immunopharmacol Immunotoxicol. 2003 May;25(2):259-71 [12784917.001]
  • [Cites] Am J Chin Med. 2003;31(2):163-9 [12856855.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4037-43 [12874003.001]
  • [Cites] Life Sci. 2003 Sep 12;73(17):2249-62 [12927594.001]
  • [Cites] Oncogene. 2003 Aug 21;22(35):5427-35 [12934102.001]
  • [Cites] Life Sci. 2003 Sep 19;73(18):2383-94 [12941440.001]
  • [Cites] Int J Oncol. 2003 Oct;23(4):1203-11 [12964005.001]
  • [Cites] Int J Oncol. 2003 Nov;23(5):1461-70 [14532991.001]
  • [Cites] Pharmacogenomics J. 2003;3(5):267-76 [12931129.001]
  • [Cites] Gynecol Oncol. 2003 Nov;91(2):332-40 [14599863.001]
  • [Cites] Br J Cancer. 2004 Jan 12;90(1):65-9 [14710208.001]
  • [Cites] Anticancer Res. 2004 Jan-Feb;24(1):303-9 [15015612.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5328-35 [15044693.001]
  • [Cites] Lab Invest. 2003 Jan;83(1):87-98 [12533689.001]
  • (PMID = 17111471.001).
  • [ISSN] 1673-1581
  • [Journal-full-title] Journal of Zhejiang University. Science. B
  • [ISO-abbreviation] J Zhejiang Univ Sci B
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Drugs, Chinese Herbal
  • [Number-of-references] 40
  • [Other-IDs] NLM/ PMC1661669
  •  go-up   go-down


79. Kung YY, Chen YC, Hwang SJ, Chen TJ, Chen FP: The prescriptions frequencies and patterns of Chinese herbal medicine for allergic rhinitis in Taiwan. Allergy; 2006 Nov;61(11):1316-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The evaluation of Chinese herbal medicines (CHM) to allergic rhinitis (AR) by large-scale pharmaco-epidemiological study is not ease found, although CHM had been reported to have potential effect for AR in some clinical trials.
  • AIMS OF THE STUDY: To explore the frequency and pattern of CHM prescriptions on AR, we have the study by analysing the population-based CHM database in Taiwan.
  • METHODS: The way for this study was linked and processed the complete traditional Chinese medicine database for Taiwanese recorded in the year 2002.
  • Association rule was applied to analyse co-prescription of CHM for patients with AR.
  • There were 35.6% of AR patients been treated by CHM.
  • The peak age of AR patients treated by CHM was at the first decade (0-10).
  • While for the combination treatments the most common prescription was the two formulae, Xiao-qing-long-tang and Shin-yi-san.
  • CONCLUSIONS: Because of the high utilization rate of the CHM treatment for AR, a large-scale randomized trial warrants further research for its efficacy and safety.
  • [MeSH-major] Drug Prescriptions. Drugs, Chinese Herbal / therapeutic use. Rhinitis, Allergic, Perennial / drug therapy

  • Genetic Alliance. consumer health - Allergic rhinitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17002708.001).
  • [ISSN] 0105-4538
  • [Journal-full-title] Allergy
  • [ISO-abbreviation] Allergy
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal
  •  go-up   go-down


80. Mourali M, Fkih C, Essoussi-Chikhaoui J, Ben Haj Hassine A, Binous N, Ben Zineb N, Boussen H: Gestational trophoblastic disease in Tunisia. Tunis Med; 2008 Jul;86(7):665-9
Genetic Alliance. consumer health - Gestational Trophoblastic Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We also precise therapeutic features used in our country and compare them to those proposed in the literature and finally suggest concrete recommendations.
  • The frequency of the CHM (complete hydatiform mole) is estimated to 68.15% of all the cases of GTD and 1 per 1347 deliveries whereas the frequency of the PHM (partial) is estimated to 30.57% and 1 per 3004 deliveries.
  • The mean gestational age at the moment of the diagnosis is of 11.5 week of amenorrhea (WA) for CHM and 11 WA for the PHM.
  • The metrorrhagia is present in 75% of the CHM and 67% of the PHM.
  • Vacuum aspiration was performed in all the CHM and in 89.5% of the PHM.
  • Two patients were treated by initial chemotherapy for invasive mole and metastatic mole.
  • 84% of the patients reached complete healing.
  • After treatment of the molar pregnancy, two patients (1.27%) recurred.
  • The classification and treatment of the GTN must be codified Modem therapy for gestational trophoblastic diseases (GTDs) has resulted in high cure rates while preserving fertility.
  • [MeSH-major] Hydatidiform Mole / epidemiology
  • [MeSH-minor] Adolescent. Adult. Female. Gestational Age. Humans. Menorrhagia / etiology. Middle Aged. Pregnancy. Retrospective Studies. Tunisia / epidemiology. Vacuum Curettage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19472728.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Tunisia
  •  go-up   go-down


81. Feng FZ, Xiang Y, Wan XR, Yin SJ, Yang XY: [Clinical characteristics and management of gestational trophoblastic disease in women aged 50 years or more]. Zhonghua Fu Chan Ke Za Zhi; 2005 Sep;40(9):605-8
Genetic Alliance. consumer health - Gestational Trophoblastic Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The lesions included 5 hydatidiform moles (13%), 19 invasive moles (50%), 12 choriocarcinomas (32%) and 2 placenta site trophoblastic tumors (5%).
  • Twenty-three cases of hydatidiform moles were diagnosed at their first visit to the hospital, and 15 of them received prophylactic chemotherapy, of whom 10 progressed to invasive mole, 3 developed lung metastasis.
  • All of the other 8 cases without prophylactic chemotherapy progressed to malignant changes with metastasis of lung.
  • The use of prophylactic chemotherapy reduced the incidence of subsequent metastasis.
  • All of 38 cases received chemotherapy.
  • Thirty-two cases underwent hysterectomy, complete remission was achieved in 91% of patients; complete remission was achieved in 2 of 6 patients without hysterectomy.
  • CONCLUSIONS: The diagnosis of pregnancy and pregnancy-related disease should be considered in the elderly women presenting with abnormal vaginal bleeding.
  • Once gestational trophoblastic disease in women aged 50 years or more is diagnosed, chemotherapy should be given as soon as possible.
  • [MeSH-major] Gestational Trophoblastic Disease / diagnosis. Gestational Trophoblastic Disease / drug therapy
  • [MeSH-minor] Choriocarcinoma / diagnosis. Choriocarcinoma / drug therapy. Choriocarcinoma / surgery. Female. Humans. Hydatidiform Mole / diagnosis. Hydatidiform Mole / drug therapy. Hydatidiform Mole / surgery. Middle Aged. Pregnancy. Prognosis. Retrospective Studies. Time Factors. Treatment Outcome. Uterine Hemorrhage / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16202316.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


82. Nizam K, Haider G, Memon N, Haider A: Gestational trophoblastic disease: experience at Nawabshah Hospital. J Ayub Med Coll Abbottabad; 2009 Jan-Mar;21(1):94-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Gestational Trophoblastic Disease (GTD) is a heterogeneous group of diseases that includes partial and complete hydatidiform mole, invasive mole, choriocarcinoma and placental site trophoblastic tumour.
  • METHODS: The case records of all the gestational trophoblastic cases during study period were analysed regarding their history, clinical examination, investigations, treatment and follow-up.
  • The main outcomes were measured in terms of duration, antecedent pregnancy, investigations, treatment and the follow-up.
  • Of these 30 cases, 21 (70%) patients had hydatidiform mole, 7 (23.3%) patients had invasive disease and 2 (6.6%) patients had choriocarcinoma.
  • Twenty three patients (76.6%) received chemotherapy while 25 (83.3%) patients had suction evacuation and 4 (13.3%) patients underwent hysterectomy.
  • Hydatidiform mole was the commonest type of trophoblastic disease in these patients.
  • [MeSH-minor] Adolescent. Adult. Choriocarcinoma / diagnosis. Choriocarcinoma / epidemiology. Choriocarcinoma / therapy. Chorionic Gonadotropin, beta Subunit, Human / blood. Female. Humans. Hydatidiform Mole / diagnosis. Hydatidiform Mole / epidemiology. Hydatidiform Mole / therapy. Hydatidiform Mole, Invasive / diagnosis. Hydatidiform Mole, Invasive / epidemiology. Hydatidiform Mole, Invasive / therapy. Incidence. Pakistan / epidemiology. Pregnancy. Retrospective Studies. Trophoblastic Tumor, Placental Site / diagnosis. Trophoblastic Tumor, Placental Site / epidemiology. Trophoblastic Tumor, Placental Site / therapy. Uterine Neoplasms / diagnosis. Uterine Neoplasms / epidemiology. Uterine Neoplasms / therapy. Young Adult

  • Genetic Alliance. consumer health - Gestational Trophoblastic Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20364752.001).
  • [ISSN] 1025-9589
  • [Journal-full-title] Journal of Ayub Medical College, Abbottabad : JAMC
  • [ISO-abbreviation] J Ayub Med Coll Abbottabad
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human
  •  go-up   go-down


83. Soper JT, Mutch DG, Schink JC, American College of Obstetricians and Gynecologists: Diagnosis and treatment of gestational trophoblastic disease: ACOG Practice Bulletin No. 53. Gynecol Oncol; 2004 Jun;93(3):575-85
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and treatment of gestational trophoblastic disease: ACOG Practice Bulletin No. 53.
  • Histologically distinct disease entities encompassed by this general terminology include complete and partial hydatidiform moles, invasive moles, gestational choriocarcinomas, and placental site trophoblastic tumors.
  • Before the advent of sensitive assays for human chorionic gonadotropin (hCG) and efficacious chemotherapy, the morbidity and mortality from gestational trophoblastic disease were substantial.
  • At present, with sensitive quantitative assays for beta-hCG and current approaches to chemotherapy, most women with malignant gestational trophoblastic disease can be cured and their reproductive function preserved.
  • [MeSH-major] Gestational Trophoblastic Disease / diagnosis. Gestational Trophoblastic Disease / therapy
  • [MeSH-minor] Female. Humans. Hydatidiform Mole / diagnosis. Hydatidiform Mole / pathology. Hydatidiform Mole / therapy. Pregnancy. Uterine Neoplasms / diagnosis. Uterine Neoplasms / pathology. Uterine Neoplasms / therapy

  • Genetic Alliance. consumer health - Gestational Trophoblastic Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15196847.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Guideline; Journal Article; Practice Guideline; Review
  • [Publication-country] United States
  • [Number-of-references] 49
  •  go-up   go-down


84. Zhang A, Sun H, Wang Z, Sun W, Wang P, Wang X: Metabolomics: towards understanding traditional Chinese medicine. Planta Med; 2010 Dec;76(17):2026-35

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As a systemic approach, metabolomics adopts a "top-down" strategy to reflect the function of organisms from the end products of the metabolic network and to understand metabolic changes of a complete system caused by interventions in a holistic context.
  • Consequently, the development of robust metabolomic platforms will greatly facilitate, for example, the understanding of the action mechanisms of TCM formulae and the analysis of Chinese herbal (CHM) and mineral medicine, acupuncture, and Chinese medicine syndromes.
  • [MeSH-major] Drugs, Chinese Herbal / adverse effects. Drugs, Chinese Herbal / metabolism. Medicine, Chinese Traditional. Metabolomics / methods
  • [MeSH-minor] Acupuncture Therapy. Animals. Biomarkers / blood. Chromatography, Liquid. Humans. Liver / drug effects. Liver / metabolism. Liver Failure / chemically induced. Liver Failure / metabolism. Magnetic Resonance Imaging. Mass Spectrometry. Systems Biology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Georg Thieme Verlag KG Stuttgart · New York.
  • (PMID = 21058239.001).
  • [ISSN] 1439-0221
  • [Journal-full-title] Planta medica
  • [ISO-abbreviation] Planta Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Drugs, Chinese Herbal
  •  go-up   go-down


85. Flower A, Liu JP, Chen S, Lewith G, Little P: Chinese herbal medicine for endometriosis. Cochrane Database Syst Rev; 2009;(3):CD006568
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Endometriosis is characterized by the presence of tissue that is morphologically and biologically similar to normal endometrium in locations outside the uterus.
  • Surgical and hormonal treatment of endometriosis have unpleasant side effects and high rates of relapse.
  • In China, treatment of endometriosis using Chinese herbal medicine (CHM) is routine and considerable research into the role of CHM in alleviating pain, promoting fertility, and preventing relapse has taken place.
  • OBJECTIVES: To review the effectiveness and safety of CHM in alleviating endometriosis-related pain and infertility.
  • SELECTION CRITERIA: Randomised controlled trials (RCTs) involving CHM versus placebo, biomedical treatment, another CHM intervention, or CHM plus biomedical treatment versus biomedical treatment were selected.
  • Neither trial compared CHM with placebo treatment.There was no evidence of a significant difference in rates of symptomatic relief between CHM and gestrinone administered subsequent to laparoscopic surgery (95.65% versus 93.87%; risk ratio (RR) 1.02, 95% confidence interval (CI) 0.93 to 1.12, one RCT).
  • There was no significant difference between the CHM and gestrinone groups with regard to the total pregnancy rate (69.6% versus 59.1%; RR 1.18, 95% CI 0.87 to 1.59, one RCT).CHM administered orally and then in conjunction with a herbal enema resulted in a greater proportion of women obtaining symptomatic relief than with danazol (RR 5.06, 95% CI 1.28 to 20.05; RR 5.63, 95% CI 1.47 to 21.54, respectively).Overall, 100% of women in all the groups showed some improvement in their symptoms.Oral plus enema administration of CHM showed a greater reduction in average dysmenorrhoea pain scores than did danazol (mean difference (MD) -2.90, 95% CI -4.55 to -1.25; P < 0.01).Combined oral and enema administration of CHM showed a greater improvement, measured as the disappearance or shrinkage of adnexal masses, than with danazol (RR 1.70, 95% CI 1.04 to 2.78).
  • For lumbosacral pain, rectal discomfort, or vaginal nodules tenderness, there was no significant difference either between CHM and danazol.
  • AUTHORS' CONCLUSIONS: Post-surgical administration of CHM may have comparable benefits to gestrinone but with fewer side effects.
  • Oral CHM may have a better overall treatment effect than danazol; it may be more effective in relieving dysmenorrhea and shrinking adnexal masses when used in conjunction with a CHM enema.
  • However, more rigorous research is required to accurately assess the potential role of CHM in treating endometriosis.
  • [MeSH-major] Drugs, Chinese Herbal / therapeutic use. Endometriosis / drug therapy
  • [MeSH-minor] Female. Gestrinone / therapeutic use. Humans. Pelvic Pain / drug therapy. Pelvic Pain / etiology. Progestins / therapeutic use. Randomized Controlled Trials as Topic

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateIn] Cochrane Database Syst Rev. 2012;5:CD006568 [22592712.001]
  • (PMID = 19588398.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 0 / Progestins; 1421533RCM / Gestrinone
  • [Number-of-references] 151
  •  go-up   go-down


86. Zhao J, Xiang Y, Wan XR, Feng FZ, Cui QC, Yang XY: [Genetic genesis of choriocarcinoma]. Zhonghua Fu Chan Ke Za Zhi; 2010 Jan;45(1):35-40
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To distinguish choriocarcinoma from gestational or non-gestational choriocarcinoma and also identify the causative pregnancy of gestational choriocarcinoma by the genetic origin through molecular genetic analysis.
  • METHODS: Twelve patients with choriocarcinoma, who had experienced surgery prior to chemotherapy were enrolled in this study.
  • Peripheral venous blood samples and formalin-fixed paraffin-embedded blocks of choriocarcinoma tissue microdissected from haematoxylin and eosin-stained sections of tissue by microdissection method were available from the patient and (or) her husband.
  • DNA was then prepared from the couples' blood samples and choriocarcinoma tissue by using standard techniques.
  • PCR amplification and fluorescent microsatellite genotyping were performed by using DNA from the couples and captured choriocarcinoma tissues.
  • The genetic contributions to the choriocarcinoma tissue were determined by comparing the fragments of genes from the choriocarcinoma tissue to those from blood samples of the couples.
  • The causative pregnancies of the 8 cases with gestational choriocarcinoma were identified as androgenetic complete hydatidiform mole (AnCHM) in six cases and normal pregnancies in two cases, respectively.
  • CONCLUSION: Microsatellite polymorphism analysis is a molecular approach for distinguishing the non-gestational choriocarcinoma from the gestational one, and also be used to identify the causative pregnancy of gestational choriocarcinoma.
  • [MeSH-major] Choriocarcinoma / genetics. DNA, Neoplasm / genetics. Hydatidiform Mole / genetics. Microsatellite Repeats / genetics. Ovarian Neoplasms / genetics. Uterine Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. Choriocarcinoma, Non-gestational / diagnosis. Choriocarcinoma, Non-gestational / genetics. Choriocarcinoma, Non-gestational / pathology. Female. Humans. Male. Polymerase Chain Reaction / methods. Polymorphism, Genetic. Pregnancy. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20367924.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


87. Man MQ, Shi Y, Man M, Lee SH, Demerjian M, Chang S, Feingold KR, Elias PM: Chinese herbal medicine (Tuhuai extract) exhibits topical anti-proliferative and anti-inflammatory activity in murine disease models. Exp Dermatol; 2008 Aug;17(8):681-7
Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • While psoriasis is one of the most common skin disorders in humans, effective, safe and inexpensive treatments are still largely unavailable.
  • Chinese herbal medicine (CHM) has been used for centuries for treating psoriasis and several reports claim that systemic administration of one such CHM, Tuhuai, mainly composed of flos sophorae, smilax glabra roxb and licorice, is effective in psoriasis.
  • However, the mechanisms by which this CHM improves psoriasis are not yet clear.
  • Moreover, drugs that specifically inhibit epidermal hyperplasia and/or inflammation are widely used to treat psoriasis.
  • As topical Tuhuai extract exhibits anti-proliferative and anti-inflammatory properties in a variety of human models of inflammatory dermatoses, Tuhuai could provide an effective, relatively safe and inexpensive therapeutic alternative for the treatment of inflammatory dermatoses, including psoriasis.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 2002 Jan;118(1):94-101 [11851881.001]
  • [Cites] J Invest Dermatol. 2000 Sep;115(3):361-7 [10951269.001]
  • [Cites] Clin Exp Dermatol. 2002 Mar;27(2):111-4 [11952700.001]
  • [Cites] Rheumatology (Oxford). 2002 Jul;41(7):741-9 [12096222.001]
  • [Cites] J Invest Dermatol. 2003 Feb;120(2):246-55 [12542530.001]
  • [Cites] J Ethnopharmacol. 2003 Mar;85(1):53-9 [12576202.001]
  • [Cites] J Pharm Pharmacol. 2003 May;55(5):691-6 [12831513.001]
  • [Cites] Inflamm Res. 2003 Aug;52(8):334-40 [14504671.001]
  • [Cites] J Dermatolog Treat. 2003 Sep;14(3):153-7 [14522625.001]
  • [Cites] N Engl J Med. 2003 Nov 20;349(21):2014-22 [14627786.001]
  • [Cites] J Bone Miner Metab. 2004;22(2):159-62 [14999528.001]
  • [Cites] J Invest Dermatol. 2004 Aug;123(2):305-12 [15245430.001]
  • [Cites] Cancer Res. 1971 Jun;31(6):851-3 [5088490.001]
  • [Cites] Br Med J (Clin Res Ed). 1986 Sep 20;293(6549):731-2 [3094629.001]
  • [Cites] J Am Acad Dermatol. 1988 Apr;18(4 Pt 1):655-62 [2967310.001]
  • [Cites] Acta Derm Venereol. 1989;69(1):35-40 [2563606.001]
  • [Cites] J Am Acad Dermatol. 1989 Jun;20(6):1088-93 [2526824.001]
  • [Cites] Am J Med. 1991 Jun;90(6):711-6 [1828327.001]
  • [Cites] Br J Dermatol. 1992 Nov;127(5):501-4 [1467290.001]
  • [Cites] Can J Gastroenterol. 1996 Oct;10(6):369-75 [9193771.001]
  • [Cites] Pharmacol Res. 1997 Oct;36(4):309-14 [9425621.001]
  • [Cites] Pharmacol Res. 1997 Nov;36(5):401-9 [9441732.001]
  • [Cites] Br J Dermatol. 1998 Mar;138(3):443-9 [9580797.001]
  • [Cites] J Interferon Cytokine Res. 1998 Jun;18(6):423-8 [9660250.001]
  • [Cites] Acta Derm Venereol. 1999 Jan;79(1):86 [10086871.001]
  • [Cites] Br J Dermatol. 1999 Aug;141(2):274-8 [10468799.001]
  • [Cites] BioDrugs. 2005;19(1):47-57 [15691217.001]
  • [Cites] Eur J Dermatol. 2005 Jan-Feb;15(1):31-6 [15701590.001]
  • [Cites] J Dermatolog Treat. 2005 Feb;16(1):37-42 [15897166.001]
  • [Cites] Br J Dermatol. 2005 Jun;152(6):1304-12 [15948997.001]
  • [Cites] J Agric Food Chem. 2005 Oct 19;53(21):8197-204 [16218664.001]
  • [Cites] Acta Dermatovenerol Croat. 2005;13(2):108-13 [16324424.001]
  • [Cites] J Allergy Clin Immunol. 2005 Dec;116(6):1350-6 [16337470.001]
  • [Cites] Br J Dermatol. 2006 Mar;154(3):460-6 [16445776.001]
  • [Cites] Ann Rheum Dis. 2006 Mar;65(3):405-7 [16150791.001]
  • [Cites] Exp Dermatol. 2006 Mar;15(3):154-60 [16480422.001]
  • [Cites] Skin Therapy Lett. 2006 Feb;11(1):1-4 [16485060.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2006 Mar;20(3):269-73 [16503885.001]
  • [Cites] J Dermatol. 2006 Feb;33(2):80-90 [16556273.001]
  • [Cites] J Drugs Dermatol. 2006 Mar;5(3):236-44 [16573256.001]
  • [Cites] Br J Dermatol. 2006 Jun;154(6):1155-60 [16704648.001]
  • [Cites] J Ethnopharmacol. 2006 Nov 3;108(1):133-41 [16730935.001]
  • [Cites] J Dermatolog Treat. 2006;17(5):288-93 [17092859.001]
  • [Cites] Clin Drug Investig. 2006;26(2):55-62 [17163236.001]
  • [Cites] World J Gastroenterol. 2007 Jan 14;13(2):250-6 [17226904.001]
  • [Cites] J Rheumatol. 2007 Feb;34(2):434-7 [17295430.001]
  • [Cites] Skin Res Technol. 2001 May;7(2):73-7 [11393207.001]
  • [Cites] J Rheumatol. 2001 Nov;28(11):2395-9 [11708409.001]
  • [Cites] Saudi Med J. 2007 Apr;28(4):642-3 [17457498.001]
  • [Cites] Int J Dermatol. 2007 May;46(5):468-74 [17472673.001]
  • [Cites] J Surg Res. 2007 Nov;143(1):58-65 [17950073.001]
  • [Cites] J Periodontol. 2000 Apr;71(4):650-6 [10807132.001]
  • [Cites] Clin Exp Dermatol. 2000 Jan;25(1):97-8 [10819606.001]
  • [Cites] Br J Dermatol. 2002 Mar;146(3):414-22 [11952541.001]
  • (PMID = 18341576.001).
  • [ISSN] 1600-0625
  • [Journal-full-title] Experimental dermatology
  • [ISO-abbreviation] Exp. Dermatol.
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / P01 AR039448-100008; United States / NIAMS NIH HHS / AR / AR050629-02; United States / NIAMS NIH HHS / AR / R01 AR019098-31; United States / NIAMS NIH HHS / AR / AR 050629; United States / NIAMS NIH HHS / AR / R01 AR050629; United States / NIAMS NIH HHS / AR / R01 AR050629-02; United States / NIAMS NIH HHS / AR / R01 AR019098; United States / PHS HHS / / P0 39448; United States / NIAMS NIH HHS / AR / AR039448-100008; None / None / / R01 AR019098-31; United States / NIAMS NIH HHS / AR / AR 19098
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Drugs, Chinese Herbal; 15646-46-5 / Oxazolone; NI40JAQ945 / Tetradecanoylphorbol Acetate
  • [Other-IDs] NLM/ NIHMS184978; NLM/ PMC2843409
  •  go-up   go-down


88. Shimizu T, Yaegashi N: [Gestational trophoblastic tumors and recent clinical information]. Gan To Kagaku Ryoho; 2002 Aug;29(8):1363-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients who score as low-risk are treated with single agent chemotherapy, such as methotrexate (MTX), and patients refractory to MTX are treated with a combination chemotherapy, EMA/CO.
  • Patients who score as high-risk are treated with EMA/CO, and patients refractory to the first line chemotherapy may be successfully treated with EP/EMA.
  • Recent epidemiological data showed that women with complete hydatidiform moles could anticipate normal reproduction in the future.
  • Studies found that pregnancies after treatment of molar pregnancy resulted in 69% full-term, live births; 8% premature deliveries; 1% ectopic pregnancies, and 0.5% stillbirths.
  • Patients with hydatidiform mole were at increased risk of developing molar pregnancy in subsequent conceptions.
  • After having one molar pregnancy, the risk of having molar disease in a future gestation was about 1%.
  • Partial hydatidiform moles were never previously proven to transform into choriocarcinoma; however, a recent study with molecular techniques clearly showed that partial moles could transform into choriocarcinoma.
  • All patients with suspected partial moles should be reviewed centrally and require hCG follow-up.
  • [MeSH-major] Trophoblastic Neoplasms / therapy. Uterine Neoplasms / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Contraceptives, Oral / adverse effects. Cyclophosphamide / administration & dosage. Dactinomycin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Hydatidiform Mole / pathology. Methotrexate / administration & dosage. Pregnancy. Prognosis. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12214462.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Contraceptives, Oral; 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate; EMA-CO protocol; VP-P protocol
  • [Number-of-references] 15
  •  go-up   go-down


89. Moosajee M, Gregory-Evans K, Ellis CD, Seabra MC, Gregory-Evans CY: Translational bypass of nonsense mutations in zebrafish rep1, pax2.1 and lamb1 highlights a viable therapeutic option for untreatable genetic eye disease. Hum Mol Genet; 2008 Dec 15;17(24):3987-4000
ZFIN. ZFIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translational bypass of nonsense mutations in zebrafish rep1, pax2.1 and lamb1 highlights a viable therapeutic option for untreatable genetic eye disease.
  • The extensive molecular genetic heterogeneity seen with inherited eye disease is a major barrier to the development of gene-based therapeutics.
  • A therapeutic intervention targeted at this abnormality would therefore potentially be relevant to a wide range of inherited eye diseases.
  • We have taken advantage of the ability of aminoglycoside drugs to suppress such nonsense mutations and partially restore full-length, functional protein in a zebrafish model of choroideraemia (chm(ru848); juvenile chorio-retinal degeneration) and in two models of ocular coloboma (noi(tu29a) and gup(m189); congenital optic fissure closure defects).
  • In vitro cell-based assays showed significant readthrough with two drugs, gentamicin and paromomycin, which was confirmed by western blot and in vitro prenylation assays.
  • Both drugs were found to reduce the size of the coloboma, providing molecular evidence that cell death is required for optic fissure remodelling.
  • These findings draw attention to the value of zebrafish models of eye disease as useful preclinical drug screening tools in studies to identify molecular mechanisms amenable to therapeutic intervention.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / genetics. Codon, Nonsense / genetics. Eye Diseases, Hereditary / drug therapy. Eye Diseases, Hereditary / genetics. Laminin / genetics. PAX2 Transcription Factor / genetics. Protein Biosynthesis / genetics. Zebrafish Proteins / genetics
  • [MeSH-minor] Animals. COS Cells. Cercopithecus aethiops. Disease Models, Animal. Dose-Response Relationship, Drug. Embryo, Nonmammalian / drug effects. Embryo, Nonmammalian / physiology. Gene Expression Regulation, Developmental / drug effects. Gentamicins / pharmacology. Gentamicins / toxicity. Paromomycin / pharmacology. Paromomycin / toxicity. Phenotype. Protein Synthesis Inhibitors / pharmacology. Zebrafish / genetics

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • SciCrunch. ZFIN: Data: Gene Expression .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18809619.001).
  • [ISSN] 1460-2083
  • [Journal-full-title] Human molecular genetics
  • [ISO-abbreviation] Hum. Mol. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Codon, Nonsense; 0 / Gentamicins; 0 / Laminin; 0 / PAX2 Transcription Factor; 0 / Protein Synthesis Inhibitors; 0 / Rep1 protein, zebrafish; 0 / Zebrafish Proteins; 0 / lamb1 protein, zebrafish; 0 / pax2a protein, zebrafish; 61JJC8N5ZK / Paromomycin
  •  go-up   go-down


90. Oshima Y, Shukunami C, Honda J, Nishida K, Tashiro F, Miyazaki J, Hiraki Y, Tano Y: Expression and localization of tenomodulin, a transmembrane type chondromodulin-I-related angiogenesis inhibitor, in mouse eyes. Invest Ophthalmol Vis Sci; 2003 May;44(5):1814-23
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and localization of tenomodulin, a transmembrane type chondromodulin-I-related angiogenesis inhibitor, in mouse eyes.
  • PURPOSE: To explore the role in the eye of tenomodulin (TeM), a chondromodulin (ChM)-I-related glycoprotein, the expression, localization, and antiangiogenic potential of TeM were investigated.
  • Antiangiogenic function included in the C terminus of TeM and ChM-I was examined in vascular endothelial cells through adenoviral gene transduction.
  • In situ hybridization of the eye tissues revealed TeM mRNA in the tendon of the extraocular muscle, the sclerocornea, the lens fiber cells, and the ganglion cell layer, inner nuclear layer cells, and pigment epithelium of the retina.
  • Production of a secreted form of TeM and ChM-I through adenoviral gene transfer caused effective autocrine suppression of cell proliferation and capillary-like morphogenesis of retina vascular endothelial cells.
  • The condition media from soluble TeM- and ChM-I-overexpressing cells also showed a marked inhibitory effect on in vitro angiogenesis.
  • CONCLUSIONS: These results indicate a potential role for TeM in prevention of vascular invasion in the mouse eye and the possibility of both TeM and ChM-I as candidates for use in gene therapy approaches to treatment of ocular angiogenesis.
  • [MeSH-minor] Adenoviridae / genetics. Animals. Blotting, Northern. Blotting, Western. Capillaries. Cell Division / drug effects. Cells, Cultured. Endothelium, Vascular / cytology. Endothelium, Vascular / drug effects. Endothelium, Vascular / metabolism. Gene Expression. Humans. Immunoenzyme Techniques. In Situ Hybridization. Intercellular Signaling Peptides and Proteins / metabolism. Intercellular Signaling Peptides and Proteins / pharmacology. Mice. Morphogenesis / drug effects. Neovascularization, Physiologic / drug effects. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Skin / metabolism. Transfection

  • MedlinePlus Health Information. consumer health - Eye Care.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12714610.001).
  • [ISSN] 0146-0404
  • [Journal-full-title] Investigative ophthalmology & visual science
  • [ISO-abbreviation] Invest. Ophthalmol. Vis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Eye Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / Lect1 protein, mouse; 0 / Membrane Glycoproteins; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / TNMD protein, human; 0 / Tnmd protein, mouse; 136362-10-2 / LECT1 protein, human
  •  go-up   go-down


91. Jauniaux E, Maymon R, Greenwold N, Hustin J, Moroz C: Diminished expression of placental isoferritin p43 component in first trimester abnormal pregnancies. Placenta; 2000 May;21(4):408-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human placental isoferritin (PLF) is a sub-type of human ferritin mainly composed of a 43 kD protein, which has an immunosuppressive activity and may be involved in the downregulation of the maternal immune system during pregnancy.
  • The aim of this study was to evaluate the distribution of p43 in the placental tissue of abnormal first trimester pregnancies.
  • Samples of villous and decidual tissues were collected between 7 and 12 weeks' gestation from 28 missed abortions and eight complete moles.
  • Samples of placental tissue from 20 normal pregnancies of similar gestational age were used as controls.
  • Compared to controls, specific p43 immunoreactivity was low in the villous syncytiotrophoblast of missed abortions and absent from all villous cellular types in complete moles.
  • These findings correlate well with the low level of maternal serum PLF found previously in early pregnancy failures and molar gestation.
  • This suggests that PLF may be involved in the pathogenesis of early pregnancy disorders related to an abnormal placentation.
  • [MeSH-major] Abortion, Missed / metabolism. Cytokines / metabolism. Ferritins / metabolism. Hydatidiform Mole / metabolism. Placenta / metabolism. Pregnancy Complications, Neoplastic. Uterine Neoplasms / metabolism
  • [MeSH-minor] Adult. Animals. Chromosome Aberrations. Female. Humans. Pregnancy. Pregnancy Trimester, First

  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Harcourt Publishers Ltd.
  • (PMID = 10833377.001).
  • [ISSN] 0143-4004
  • [Journal-full-title] Placenta
  • [ISO-abbreviation] Placenta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Cytokines; 9007-73-2 / Ferritins
  •  go-up   go-down


92. Sasaki S, Sasaki Y, Iino K: Recurrent gestational trophoblastic disease in a case of suspected quiescent gestational trophoblastic disease: a case report. J Reprod Med; 2010 Jul-Aug;55(7-8):317-20
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • GTD is managed well in Japan according to Japanese guidelines for the treatment of GTD, and we have almost conquered this disease during recent decades.
  • Many young doctors now have little opportunity to see typical classic mole and participate in the management of GTD during their residency training.
  • CASE: The patient was a 46-year-old woman, G3, P2, A1, who underwent dilation and curettage for complete mole 7 years earlier. hCG elevated during follow-up, and a 50-mg methotrexate single injection was given. hCG decreased to 20-30 mIU/mL, but it then plateaued for 3 months.
  • Three years and 3 months later beta-hCG went up to 3.1 ng/mL, but magnetic resonance imaging and computed tomography scans did not show any evidence of tumor.
  • We emphasize that sufficient initial chemotherapy is very important to reduce the risk of recurrence.
  • [MeSH-major] Choriocarcinoma / diagnosis. Hydatidiform Mole / pathology. Neoplasms, Second Primary / diagnosis. Uterine Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Chorionic Gonadotropin / blood. Dilatation and Curettage. Etoposide / therapeutic use. Female. Humans. Methotrexate / therapeutic use. Middle Aged. Pregnancy

  • Genetic Alliance. consumer health - Gestational Trophoblastic Disease.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20795345.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Chorionic Gonadotropin; 6PLQ3CP4P3 / Etoposide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


93. Belfort P, Baptista AM, Valle Filho OC: Gestational trophoblastic disease: Regional perspective in Rio de Janeiro, Brazil. J Reprod Med; 2010 May-Jun;55(5-6):258-60
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All cases of complete and partial moles and of gestational trophoblastic neoplasia (GTN) were included and analyzed.
  • Diagnosis, uterine evacuation, follow-up, chemotherapy and hysterectomy were reviewed in all patients.
  • RESULTS: The historical progression of molar pregnancy to GTN was 19.1%, decreasing to 11.6% in the last 9 years.
  • [MeSH-major] Hydatidiform Mole / epidemiology. Uterine Neoplasms / epidemiology
  • [MeSH-minor] Brazil / epidemiology. Combined Modality Therapy / statistics & numerical data. Female. Humans. Incidence. Pregnancy. Prevalence. Referral and Consultation / statistics & numerical data. Retrospective Studies

  • Genetic Alliance. consumer health - Gestational Trophoblastic Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20626183.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Jong MS, Hwang SJ, Chen YC, Chen TJ, Chen FJ, Chen FP: Prescriptions of Chinese herbal medicine for constipation under the national health insurance in Taiwan. J Chin Med Assoc; 2010 Jul;73(7):375-83
MedlinePlus Health Information. consumer health - Constipation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to determine the frequency of use and prescriptive patterns of Chinese herbal medicine (CHM) in treating constipation by analyzing the claims data of traditional Chinese medicine (TCM) from the National Health Insurance (NHI) in Taiwan.
  • Visit files with the single diagnostic coding of constipation (ICD-9-CM code 564.0) were extracted to analyze the frequency and pattern of corresponding CHM prescriptions.
  • The association rule was applied to analyze the co-prescription of CHM in treating constipation.
  • RESULTS: There were 152,564 subjects who visited TCM clinics only for constipation in Taiwan during 2004 and received a total of 387,268 CHM prescriptions.
  • Female subjects used CHM for constipation more frequently than male subjects (female:male = 3.31:1).
  • According to the association rule, the most common prescribed pattern of 2-drug combination of CHM for treating constipation was Ban-xia-xie-xin-tang plus Ma-zi-ren-wan, while the 3-drug combination of CHM was Fang-feng-tong-sheng-san, Rheum palmatum and Ma-zi-ren-wan.
  • Further clinical trials are needed to evaluate the efficacy and safety of these CHMs in treating constipation.
  • [MeSH-major] Constipation / drug therapy. Drugs, Chinese Herbal / therapeutic use. National Health Programs
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Clinical Trials as Topic. Drug Prescriptions. Drug Utilization. Female. Humans. Male. Medicine, Chinese Traditional. Middle Aged. Taiwan

  • Genetic Alliance. consumer health - Constipation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier. Published by Elsevier B.V. All rights reserved.
  • [CommentIn] J Chin Med Assoc. 2010 Oct;73(10):511-2 [21051026.001]
  • (PMID = 20688304.001).
  • [ISSN] 1728-7731
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal
  •  go-up   go-down


95. Dengfeng W, Taixiang W, Lina H, Marjoribanks J, Guanjian L, Haijun J, Ying S, Jing Z: Chinese herbal medicines in the treatment of ectopic pregnancy. Cochrane Database Syst Rev; 2007;(4):CD006224
MedlinePlus Health Information. consumer health - Ectopic Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chinese herbal medicines in the treatment of ectopic pregnancy.
  • BACKGROUND: Traditional Chinese herbal medicine (CHM) has been used widely in Chinese hospitals to treat ectopic pregnancy.
  • OBJECTIVES: To determine the effectiveness and safety of CHM in the treatment of ectopic pregnancy.
  • SELECTION CRITERIA: Randomised controlled trials (RCT) on the use of CHM for the treatment of ectopic pregnancy.
  • We could not reach a definitive conclusion from the results.
  • The pooled result showed that adding a Western medicine to CHM resulted in a significantly higher treatment success rate than with CHM alone (RR 1.33, 95% CI 1.08 to 1.63).
  • When CHM plus Western medicine was compared to CHM alone for the time to disappearance of abdominal pain, again the results favoured the arm that included Western medicine (RR -2.09, 95% CI -4.14 to -0.04).
  • Results were inconsistent for the time required for human chorionic gonadotropin (beta-hCG) to return to normal.
  • One study favoured CHM plus Western medicine over Western medicine (with or without placebo) (WMD -6.68, 95% CI -11.49 to -1.87); when CHM plus Western medicine was compared to CHM alone the results favoured the arm that included Western medicine (WMD -8.12, 95% CI -10.89 to -5.53).
  • AUTHORS' CONCLUSIONS: We have not found any well-designed trials investigating traditional Chinese herbal medicines in the treatment of ectopic pregnancy.
  • We cannot support or refute any CHM preparation for clinical use on the basis of evidence from randomised controlled trials.
  • [MeSH-major] Drugs, Chinese Herbal / therapeutic use. Pregnancy, Ectopic / drug therapy
  • [MeSH-minor] Female. Humans. Pregnancy. Randomized Controlled Trials as Topic

  • Genetic Alliance. consumer health - Ectopic Pregnancy.
  • Genetic Alliance. consumer health - Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateIn] Cochrane Database Syst Rev. 2011;(7):CD006224 [21735404.001]
  • (PMID = 17943898.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal
  • [Number-of-references] 193
  •  go-up   go-down


96. Jain KA: Gestational trophoblastic disease: pictorial review. Ultrasound Q; 2005 Dec;21(4):245-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ultrasound is the modality of choice for evaluating normal or abnormal first trimester pregnancy.
  • Partial or complete hydatidiform moles can be diagnosed in early gestation.
  • Sometimes molar pregnancies have very unusual sonographic appearances.
  • Sonography and Doppler imaging are helpful in diagnosing gestational trophoblastic disease, in determining whether invasive disease is present, in detecting recurrent disease, and in following the effectiveness of chemotherapy.
  • [MeSH-major] Gestational Trophoblastic Disease / ultrasonography. Pregnancy Complications, Neoplastic / ultrasonography. Pregnancy Outcome. Ultrasonography, Doppler, Color
  • [MeSH-minor] Adult. Choriocarcinoma / physiopathology. Choriocarcinoma / ultrasonography. Education, Medical, Continuing. Female. Humans. Hydatidiform Mole / physiopathology. Hydatidiform Mole / ultrasonography. Middle Aged. Neoplasm Staging. Pregnancy. Sensitivity and Specificity. Severity of Illness Index

  • Genetic Alliance. consumer health - Gestational Trophoblastic Disease.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16344728.001).
  • [ISSN] 0894-8771
  • [Journal-full-title] Ultrasound quarterly
  • [ISO-abbreviation] Ultrasound Q
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 41
  •  go-up   go-down


97. Xue WC, Khoo US, Ngan HY, Chan KY, Chiu PM, Tsao SW, Cheung AN: Minichromosome maintenance protein 7 expression in gestational trophoblastic disease: correlation with Ki67, PCNA and clinicopathological parameters. Histopathology; 2003 Nov;43(5):485-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: To assess the proliferative activity of gestational trophoblastic disease (GTD) using one of the novel proliferation markers (MCM7) and to determine its prognostic value in hydatidiform mole (HM).
  • METHODS AND RESULTS: Immunohistochemical staining for MCM7 was performed on 122 samples of paraffin-embedded trophoblastic tissues including 22 normal first-trimester placentas, 12 term placentas, 12 spontaneous miscarriages (SM), 21 partial moles (PM), 44 complete hydatidiform moles (CM), and 11 choriocarcinomas (CCA).
  • Eighteen of the 65 patients with HM developed persistent trophoblastic disease (PTD) requiring chemotherapy.
  • There was no significant difference in MCM7 indices between the patients who developed PTD and those who did not (P = 0.312).
  • CONCLUSIONS: We conclude that MCM7 is useful in differentiating molar and non-molar gestations but is not helpful in discriminating PM from CM or in predicting PTD.
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Placenta / metabolism. Placenta / pathology. Pregnancy. Prognosis

  • Genetic Alliance. consumer health - Gestational Trophoblastic Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14636275.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen
  •  go-up   go-down


98. Olvera M, Harris S, Amezcua CA, McCourty A, Rezk S, Koo C, Felix JC, Brynes RK: Immunohistochemical expression of cell cycle proteins E2F-1, Cdk-2, Cyclin E, p27(kip1), and Ki-67 in normal placenta and gestational trophoblastic disease. Mod Pathol; 2001 Oct;14(10):1036-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study we investigated the immunostaining patterns of G(1) restriction point and G(1)-S regulatory proteins E2F-1, Cdk2, cyclin E, p27(kip1), and the proliferation marker Ki-67 on routinely processed sections of 29 hydatidiform moles (10 partial moles and 19 complete moles, including 9 persistent moles), 7 choriocarcinomas, and 7 normal placentas.
  • E2F-1 was uniquely expressed by trophoblasts of moles and choriocarcinoma.
  • Cyclin E was maximally expressed by complete moles and choriocarcinomas, and showed an inverse relationship with the cyclin-dependent kinase inhibitor p27(kip1).
  • However, we did not find distinguishing features between complete moles that spontaneously resolved after evacuation and persistent moles that required chemotherapy.
  • The different expression patterns of cyclin E and E2F-1 in partial and complete moles may be useful in distinguishing these two entities.
  • [MeSH-minor] Choriocarcinoma / metabolism. Choriocarcinoma / pathology. Cyclin E / biosynthesis. Cyclin-Dependent Kinase 2. Cyclin-Dependent Kinase Inhibitor p27. Cyclin-Dependent Kinases / biosynthesis. E2F Transcription Factors. E2F1 Transcription Factor. Female. Humans. Hydatidiform Mole / metabolism. Hydatidiform Mole / pathology. Immunohistochemistry. Pregnancy. Protein-Serine-Threonine Kinases / biosynthesis. Transcription Factors / biosynthesis. Tumor Suppressor Proteins / biosynthesis. Uterine Neoplasms / metabolism. Uterine Neoplasms / pathology

  • Genetic Alliance. consumer health - Gestational Trophoblastic Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11598175.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Cyclin E; 0 / DNA-Binding Proteins; 0 / E2F Transcription Factors; 0 / E2F1 Transcription Factor; 0 / E2F1 protein, human; 0 / Ki-67 Antigen; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.22 / CDC2-CDC28 Kinases; EC 2.7.11.22 / CDK2 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 2; EC 2.7.11.22 / Cyclin-Dependent Kinases
  •  go-up   go-down


99. Khabouze S, Erchidi IE, Bouchikhi C, Chahtane A, Kharbach A, Chaoui A: [Gestational trophoblastic diseases. Apropos of 105 cases]. Gynecol Obstet Fertil; 2002 Jan;30(1):42-9
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of this study, one listed 72 cases of complete mole hydatiforme with 5 cases of sacrofetal pregnancy.
  • The invasive mole is found in 4 cases and the choriocarcinoma in 24 cases.
  • The treatment of the trophoblastic disease varies simple endo-uterine aspiration (85%) until the chemotherapy treatment (32.4%), the hysterectomy was indicated in a third of the cases.
  • The evolution of the non complicated mole hydatiforme was good in 100% of the cases, it quasi totality of the invasive moles presented a complete remission.
  • In order to improve the forecast of these diseases, the diagnosis must be early with an adequate treatment and a rigorous monitoring.
  • [MeSH-major] Hydatidiform Mole / epidemiology. Uterine Neoplasms / epidemiology
  • [MeSH-minor] ABO Blood-Group System. Adolescent. Adult. Choriocarcinoma / diagnosis. Choriocarcinoma / epidemiology. Choriocarcinoma / therapy. Female. Humans. Middle Aged. Parity. Pregnancy. Socioeconomic Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11875864.001).
  • [ISSN] 1297-9589
  • [Journal-full-title] Gynécologie, obstétrique & fertilité
  • [ISO-abbreviation] Gynecol Obstet Fertil
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / ABO Blood-Group System
  •  go-up   go-down


100. Varandas L, Julien M, Gomes A, Rodrigues P, Van Lerberghe W, Malveiro F, Aguiar P, Kolsteren P, Van Der Stuyft P, Hilderbrand K, Labadarios D, Ferrinho P: A randomised, double-blind, placebo-controlled clinical trial of vitamin A in severe malaria in hospitalised Mozambican children. Ann Trop Paediatr; 2001 Sep;21(3):211-22
Hazardous Substances Data Bank. VITAMIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Children aged between 6 and 72 months admitted to the paediatric wards of the Central Hospital of Maputo (CHM), Mozambique with a diagnosis of severe malaria were randomly assigned either to a control group (placebo) or an experimental group (vitamin A) and were followed up 6 weeks after discharge.
  • In the supplemented group, 4/82 (4.9%) of the children developed neurological sequelae vs 2/78 (2.6%) in the placebo group (RR = 1.90; 95% CI 0.36-10.09; p = 0.682).
  • [MeSH-major] Malaria, Falciparum / drug therapy. Vitamin A / therapeutic use
  • [MeSH-minor] Child. Child, Preschool. Double-Blind Method. Female. Follow-Up Studies. Hospitalization. Humans. Infant. Length of Stay. Malaria, Cerebral / drug therapy. Male. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Malaria.
  • MedlinePlus Health Information. consumer health - Vitamin A.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11579859.001).
  • [ISSN] 0272-4936
  • [Journal-full-title] Annals of tropical paediatrics
  • [ISO-abbreviation] Ann Trop Paediatr
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 11103-57-4 / Vitamin A
  •  go-up   go-down






Advertisement